



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N	A2	(11) International Publication Number: WO 97/47731
		(43) International Publication Date: 18 December 1997 (18.12.97)
<p>(21) International Application Number: PCT/US97/09743</p> <p>(22) International Filing Date: 10 June 1997 (10.06.97)</p> <p>(30) Priority Data: 60/019,940 14 June 1996 (14.06.96) US</p> <p>(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KINNEY, Anthony, J. [GB/US]; 609 Lore Avenue, Wilmington, DE 19809 (US). FADER, Gary, Michael [US/US]; 100 Woods Lane, Landenberg, PA 19350 (US).</p> <p>(74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
(54) Title: SUPPRESSION OF SPECIFIC CLASSES OF SOYBEAN SEED PROTEIN GENES		
(57) Abstract		
<p>This invention concerns the construction of transgenic soybean lines wherein the expression of genes encoding seed storage proteins are modulated to effect a change in seed storage protein profile of transgenic plants. Modification of the seed storage protein profile can result in the production of novel soy protein products with unique and valuable functional characteristics.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE
SUPPRESSION OF SPECIFIC CLASSES
OF SOYBEAN SEED PROTEIN GENES

FIELD OF THE INVENTION

5 This invention concerns the construction of transgenic soybean lines wherein the expression of genes encoding seed storage proteins is modified to effect a change in seed storage protein profile of transgenic plants. Such modified transgenic soybean lines are used for the production of novel soy protein products with unique and valuable functional characteristics.

BACKGROUND OF THE INVENTION

10 Soybean seeds contain from 35% to 55% protein on a dry weight basis. The majority of this protein is storage protein, which is hydrolyzed during germination to provide energy and metabolic intermediates needed by the developing seedling. The soybean seed's storage protein is an important
15 nutritional source when harvested and utilized as a livestock feed. In addition, it is now generally recognized that soybeans are the most economical source of protein for human consumption. Soy protein or protein isolates are already used extensively for food products in different parts of the world. Much effort has been devoted to improving the quantity and quality of the storage protein in soybean
20 seeds.

The seeds of most plant species contain what are known in the art as seed storage proteins. These have been classified on the basis of their size and solubility (Higgins, T. J. (1984) *Ann. Rev. Plant Physiol.* 35:191-221). While not every class is found in every species, the seeds of most plant species contain
25 proteins from more than one class. Proteins within a particular solubility or size class are generally more structurally related to members of the same class in other species than to members of a different class within the same species. In many species, the seed proteins of a given class are often encoded by multigene families, sometimes of such complexity that the families can be divided into subclasses
30 based on sequence homology.

There are two major soybean seed storage proteins: glycinin (also known as the 11S globulins) and β -conglycinin (also known as the 7S globulins). Together, they comprise 70 to 80% of the seed's total protein, or 25 to 35% of the seed's dry weight. Glycinin is a large protein with a molecular weight of about 360 kDa. It
35 is a hexamer composed of the various combinations of five major isoforms (commonly called subunits) identified as G1, G2, G3, G4 and G5. Each subunit is in turn composed of one acidic and one basic polypeptide held together by a disulfide bond. Both the acidic and basic polypeptides of a single subunit are coded for by a single gene. Hence, there are five non-allelic genes that code for

the five glycinin subunits. These genes are designated Gy1, Gy2, Gy3, Gy4 and Gy5, corresponding to subunits G1, G2, G3, G4 and G5, respectively (Nielsen, N. C. et al. (1989) *Plant Cell* 1:313-328).

Genomic clones and cDNA's for glycinin subunit genes have been
5 sequenced and fall into two groups based on nucleotide and amino acid sequence similarity. Group I consists of Gy1, Gy2, and Gy3, whereas Group II consists of Gy4 and Gy5. There is greater than 85% similarity between genes within a group (i.e., at least 85% of the nucleotides of Gy1, Gy2 and Gy3 are identical, and at least 85% of the nucleotides of Gy4 and Gy5 are identical), but only 42% to 46%
10 similarity between the genes of Group I and Group II.

β -Conglycinin (a 7S globulin) is a heterogeneous glycoprotein with a molecular weight ranging from 150 and 240 kDa. It is composed of varying combinations of three highly negatively charged subunits identified as α , α' and β . cDNA clones representing the coding regions of the genes encoding the α and α' subunits have been sequenced and are of similar size; sequence identity is
15 limited to 85%. The sequence of the cDNA representing the coding region of the β subunit, however, is nearly 0.5 kb smaller than the α and α' cDNAs. Excluding this deletion, sequence identity to the α and α' subunits is 75-80%. The three classes of β -conglycinin subunits are encoded by a total of 15 subunit genes
20 clustered in several regions within the genome soybean (Harada, J. J. et al. (1989) *Plant Cell* 1:415-425).

New soy based products such as protein concentrates, isolates, and textured protein products are increasingly utilized in countries that do not necessarily accept traditional oriental soy based foods. Use of these new products
25 in food applications, however, depends on local tastes and functional characteristic of the protein products relative to recipe requirements. Over the past 10 years, significant effort has been aimed at understanding the functional characteristics of soybean proteins. Examples of functional characteristics include water sorption parameters, wettability, swelling, water holding, solubility,
30 thickening, viscosity, coagulation, gelation characteristics and emulsification properties. A large portion of this body of research has focused on study of the β -conglycinin and glycinin proteins individually, as well as how each of these proteins influences the soy protein system as a whole (Kinsella, J. E. et al. (1985) *New Protein Foods* 5:107-179; Morr, C. V. (1987) *JAOCs* 67:265-271; Peng, L. C. et al. (1984) *Cereal Chem* 61:480-489). Because functional properties are
35 directly related to physiochemical properties of proteins, the structural differences of β -conglycinin and glycinin result in these two proteins having significantly different functional characteristics. Differences in thermal aggregation, emulsifying properties, and water holding capacity have been reported. In

addition, gelling properties vary as well, with glycinin forming gels that have greater tensile strain, stress, and shear strength, better solvent holding capacity, and lower turbidity. However, soy protein products produced today are a blend of both glycinin and β -conglycinin and therefore have functional characteristics dependent on the blend of glycinin's and β -conglycinin's individual characteristics. For example, when glycinin is heated to 100°C, about 50% of the protein is rapidly converted into soluble aggregates. Further heating results in the enlargement of the aggregates and in their precipitation. The precipitate consists of the glycinin's basic polypeptides; the acidic polypeptides remain soluble. The presence of β -conglycinin inhibits the precipitation of the basic polypeptides by forming soluble complexes with them. Whether heat denaturation is desirable or not depends on the intended use. If one could produce soy protein products containing just one or the other storage protein, products requiring specific physical characteristics derived from particular soy proteins would become available or would be more economical to produce.

Over the past 20 years, soybean lines lacking one or more of the various storage protein subunits (null mutations) have been identified in the soybean germplasm or produced using mutational breeding techniques. Breeding efforts to combine mutational events have resulted in soybean lines whose seeds contain about half the normal amount of β -conglycinin (Takashashi, K. et al. (1994) *Breeding Science* 44:65-66; Kitamura, J. (1995) *JARQ* 29:1-8). The reduction of β -conglycinin is controlled by three independent recessive mutations. Recombining glycinin subunit null mutations have resulted in lines whose seeds have significantly reduced amounts of glycinin (Kitamura, J. (1995) *JARQ* 29:1-8). Again, reduction is controlled by three independent recessive mutations. Developing agronomically viable soybean varieties from the above lines, in which the seed contains only glycinin or β -conglycinin, will be time consuming and costly. Each cross will result in the independent segregation of the three mutational events. In addition, each mutational event will need to be in the homozygous state. Development of high yielding agronomically superior soybean lines will require the screening and analysis of a large number of progeny over numerous generations.

Antisense technology has been used to reduce specific storage proteins in seeds. In *Brassica napus*, napin (a 2S albumin) and cruciferin (an 11S globulin) are the two major storage proteins, comprising about 25% and 60% of the total seeds protein, respectively. Napin proteins are coded for by a large multi-gene family of up to 16 genes; several cDNA and genomic clones have been sequenced (Josefsson, L.-G. et al. (1987) *J. Biol. Chem.* 262:12196-12201; Schofield, S. and Crouch, M. L. (1987) *J. Biol. Chem.* 262:12202-12208). The genes exhibit

greater than 90% sequence identity in both their coding and flanking regions. The cruciferin gene family is equally complex, comprising 3 subfamilies with a total of 8 genes (Rodin, J. et al. (1992) *Plant Mol. Biol.* 20:559-563). Kohno-Murase et al. ((1994) *Plant Mol. Biol.* 26:1115-1124) demonstrated that a napin antisense gene using the napA gene driven by the napA promoter could be used to construct transgenic plants whose seeds contained little or no napin.

The same group (Kohno-Murase et al. (1995) *Theoret. Applied Genetics* 91:627-631) attempted to reduce cruciferin (11S globulin) expression in *Brassica napus* by expressing an antisense form of a cruciferin gene (cruA, encoding an alpha 2/3 isoform) under the control of the napA promoter. In this case the results were more complex. The cruciferins are divided into three subclasses based on sequence identity (alpha 1, 2/3, and 4); the classes each have from 60-75% sequence identity with each other (Rodin, J. et al. (1992) *Plant Mol. Biol.* 20:559-563). Expression of the antisense gene encoding the alpha 2/3 isoform resulted in lower levels of the alpha 1 and 2/3 forms. However, there was no reduction in the expression of the alpha 4 class.

Antisense technology was used to reduce the level of the seed storage protein, glutelin, in rice. Expression of the seed specific glutelin promoter operably linked to the full length antisense glutelin coding region resulted in about a 25% reduction in glutelin protein levels (U.S. Patent No. 5,516,668).

SUMMARY OF THE INVENTION

The instant invention provides a method for reducing the quantity glycinin or β -conglycinin (11S or 7S globulins, respectively) seed storage proteins in soybeans. In one embodiment, cosuppression technology was used to suppress the expression of genes encoding the 7S-globulin class of seed protein genes. Genes encoding either two (α and α') or all three subclasses (α , α' and β) of 7S globulins were suppressed by expression of the gene encoding a single subclass (α) of β -conglycinin, resulting in soybean lines with altered seed storage profiles. In another embodiment, a method for suppressing two completely different genes, only one of which is a seed protein gene, is presented, allowing for multiple changes in seed composition. Surprisingly, expression of a chimeric gene comprising the promoter region of a soybean seed storage protein operably linked to the coding region of a soybean gene whose expression alters the fatty acid profile of transgenic soybean seeds resulted in simultaneous alteration of two distinct phenotypic traits: seed storage protein profile and seed oil profile.

The method for reducing the quantity of soybean seed storage protein taught herein comprises the following steps:

- (a) constructing a chimeric gene comprising (i) a nucleic acid fragment encoding a promoter that is functional in the cells of

soybean seeds, (ii) a nucleic acid fragment encoding all or a portion of a soybean seed storage protein placed in sense or antisense orientation relative to the promoter of (i), and (iii) a transcriptional termination region;

- 5 (b) creating a transgenic soybean cell by introducing into a soybean cell the chimeric gene of (a); and
- (c) growing the transgenic soybean cells of step (b) under conditions that result in expression of the chimeric gene of step (a)
- wherein the quantity of one or more members of a class of soybean seed storage protein subunits is reduced when compared to soybeans not containing the
- 10 chimeric gene of step (a).

DETAILED DESCRIPTION OF THE INVENTION

BRIEF DESCRIPTION OF THE SEQUENCE DESCRIPTIONS

- The invention can be more fully understood from the following detailed description and the Sequence Descriptions which form a part of this application.
- 15 The Sequence Descriptions contain the three letter codes for amino acids as defined in 37 C.F.R. 1.822 which are incorporated herein by reference.

SEQ ID NO:1 shows the 5' to 3' nucleotide sequence encoding the α subunit of the β -conglycinin soybean seed storage protein.

- 20 SEQ ID NO:2 shows the 5' to 3' nucleotide sequence encoding the α' subunit of the β -conglycinin soybean seed storage protein.

SEQ ID NO:3 shows the 5' to 3' nucleotide sequence encoding the β subunit of the β -conglycinin soybean seed storage protein.

- SEQ ID NOS:4 and 5 show the nucleotide sequences of the PCR primers ConS and Con1.4a (respectively) used to isolate nucleic acid fragments encoding the α and α' subunits of the β -conglycinin soybean seed storage protein.
- 25

SEQ ID NOS:6 and 7 show nucleotide sequences of the PCR primers Con.09 and Con.8 (respectively) used to distinguish nucleic acid fragments encoding the α and α' subunits of the β -conglycinin soybean seed storage protein.

- 30 SEQ ID NOS:8 and 9 show the nucleotide sequences of the PCR primers ConSa and Con1.9a (respectively) used to isolate full length cDNAs encoding the α and α' subunits of the β -conglycinin soybean seed storage protein.

- SEQ ID NO:10 shows the nucleotide sequence of the PCR primer Con.1.0 used to confirm the full length cDNA encoding the α and α' subunits of the
- 35 β -conglycinin soybean seed storage protein.

SEQ ID NOS:11, 12 and 13 show the 5' to 3' nucleotide sequences encoding the Gyl, Gy2 and Gy3 subunits (respectively) of the group I glycinin soybean seed storage protein.

SEQ ID NOS:14 and 15 show the 5' to 3' nucleotide sequences encoding the Gy4 and Gy5 subunits (respectively) of the group II glycinin soybean seed storage protein.

SEQ ID NOS:16, 17 and 18 show the nucleotide sequences of the PCR primers G1-1, G1-1039 and G1-1475 (respectively) used to isolate the cDNAs encoding the subunits of the group I glycinin soybean seed storage protein.

SEQ ID NOS:19, 20 and 21 show the nucleotide sequences of the PCR primers G4-7, G4-1251, and G4-1670 (respectively) used to isolate the cDNA encoding the subunits of the group II glycinin soybean seed storage protein.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a restriction map of plasmid pML70, used as an intermediate cloning vehicle in construction of chimeric genes of the instant invention.

Figure 2 is a restriction map of plasmid pCW109, used as an intermediate cloning vehicle in construction of chimeric genes of the instant invention.

Figure 3 is a restriction map of plasmid pKS18HH, used as an intermediate cloning vehicle in construction of chimeric genes of the instant invention.

Figure 4 is a restriction map of plasmid pJo1. This plasmid was derived by cloning the plant transcriptional unit KTi promoter/truncated α subunit of β -conglycinin/KTi 3' end into the BamH I site of pKS18HH.

Figure 5 is an SDS-PAGE gel of extracted protein from somatic embryos transformed with pJo1.

Figure 6 is a restriction map of plasmid pBS43. This plasmid comprises a nucleic acid sequence encoding the *Glycine max* microsomal delta-12 desaturase under the transcriptional control of the soybean β -conglycinin promoter.

Figure 7 is an SDS-PAGE gel of extracted protein from soybean seeds obtained from plants transformed with pBS43.

Figure 8 is a restriction map of plasmid pJo3. This plasmid was derived by cloning the plant transcriptional unit KTi promoter/full length cDNA of the α subunit of β -conglycinin/KTi 3' end into the HindIII site of pKS18HH.

Figure 9 is a restriction map of plasmid pRB20. This plasmid was derived by cloning the transcriptional unit β -conglycinin promoter/Phaseolin 3' end into the HindIII site of pKS18HH. It is used as an intermediate cloning vehicle in construction of chimeric genes of the instant invention.

BIOLOGICAL DEPOSITS

The following plasmids have been deposited under the terms of the Budapest Treaty at American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852, and bear the following accession numbers:

<u>Plasmid</u>	<u>Accession Number</u>	<u>Date of Deposit</u>
pJo1	ATCC 97614	June 15, 1996
pBS43	ATCC 97619	June 19, 1996
pJo3	ATCC 97615	June 15, 1996

DEFINITIONS

In the context of this disclosure, a number of terms shall be used. The term "nucleic acid" refers to a large molecule which can be single-stranded or double-stranded, composed of monomers (nucleotides) containing a sugar, a phosphate and either a purine or pyrimidine. A "nucleic acid fragment" is a fraction of a given nucleic acid molecule. In higher plants, deoxyribonucleic acid (DNA) is the genetic material while ribonucleic acid (RNA) is involved in the transfer of the information in DNA into proteins. A "genome" is the entire body of genetic material contained in each cell of an organism. The term "nucleotide sequence" refers to the sequence of DNA or RNA polymers, which can be single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases capable of incorporation into DNA or RNA polymers.

As used herein, the term "homologous to" refers to the relatedness between the nucleotide sequence of two nucleic acid molecules or between the amino acid sequences of two protein molecules. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.); or by the comparison of sequence similarity between two nucleic acids or proteins, such as by the method of Needleman et al. ((1970) *J. Mol. Biol.* 48:443-453).

As used herein, "essentially similar" refers to DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. It is therefore understood that the invention encompasses more than the specific exemplary sequences. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alteration in the gene sequence which reflect the degeneracy of the genetic code, or which results in the production of a chemically equivalent amino acid at a given site, are contemplated; thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another hydrophobic amino acid residue such as glycine, valine, leucine, or isoleucine. Similarly, changes which result in substitution of one

negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

Moreover, the skilled artisan recognizes that "essentially similar" sequences encompassed by this invention can also be defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C), with the sequences exemplified herein.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding) and following (3' non-coding) the coding region. "Native" gene refers to an isolated gene with its own regulatory sequences as found in nature. "Chimeric gene" refers to a gene that comprises heterogeneous regulatory and coding sequences not found in nature. "Endogenous" gene refers to the native gene normally found in its natural location in the genome and is not isolated. A "foreign" gene refers to a gene not normally found in the host organism but that is introduced by gene transfer.

"Coding sequence" or "coding region" refers to a DNA sequence that codes for a specific protein and excludes the non-coding sequences. It may constitute an "uninterrupted coding sequence", i.e., lacking an intron or it may include one or more introns bounded by appropriate splice junctions. An "intron" is a nucleotide sequence that is transcribed in the primary transcript but that is removed through cleavage and re-ligation of the RNA within the cell to create the mature mRNA that can be translated into a protein.

"Initiation codon" and "termination codon" refer to a unit of three adjacent nucleotides in a coding sequence that specifies initiation and chain termination, respectively, of protein synthesis (mRNA translation). "Open reading frame" refers to the coding sequence uninterrupted by introns between initiation and termination codons that encodes an amino acid sequence.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that

can be translated into protein by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to RNA transcript that includes the mRNA. "Antisense RNA" refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene. The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence.

As used herein, "suitable regulatory sequences" refer to nucleotide sequences in native or chimeric genes that are located upstream (5'), within, or downstream (3') to the nucleic acid fragments of the invention, which control the expression of the nucleic acid fragments of the invention. The term "expression", as used herein, refers to the transcription and stable accumulation of the sense (mRNA) or the antisense RNA derived from the nucleic acid fragment(s) of the invention that, in conjunction with the protein apparatus of the cell, results in altered phenotypic traits. Expression of the gene involves transcription of the gene and translation of the mRNA into precursor or mature proteins. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of preventing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Cosuppression" refers to the expression of a foreign gene which has substantial homology to an endogenous gene resulting in the suppression of expression of both the foreign and the endogenous gene. "Altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms. The skilled artisan will recognize that the phenotypic effects contemplated by this invention can be achieved by alteration of the level of gene product(s) produced in transgenic organisms relative to normal or non-transformed organisms, namely a reduction in gene expression mediated by antisense suppression or cosuppression.

"Promoter" refers to a DNA sequence in a gene, usually upstream (5') to its coding sequence, which controls the expression of the coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription. In artificial DNA constructs, promoters can also be used to transcribe antisense RNA. Promoters may also contain DNA sequences that are involved in the binding of protein factors which control the effectiveness of transcription initiation in response to physiological or developmental conditions. It may also contain enhancer elements. An "enhancer" is a DNA sequence which can stimulate promoter activity. It may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a

promoter. "Constitutive promoters" refers to those that direct gene expression in all tissues and at all times. "Tissue-specific" or "development-specific" promoters as referred to herein are those that direct gene expression almost exclusively in specific tissues, such as leaves or seeds, or at specific development stages in a tissue, such as in early or late embryogenesis, respectively.

The "3' non-coding sequences" refers to the DNA sequence portion of a gene that contains a polyadenylation signal and any other regulatory signal capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor.

The term "operably linked" refers to nucleic acid sequences on a single nucleic acid molecule which are associated so that the function of one is affected by the other. For example, a promoter is operably linked with a structural gene when it is capable of affecting the expression of that structural gene (i.e., that the structural gene is under the transcriptional control of the promoter).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms.

This invention concerns the construction of transgenic soybean lines wherein the expression of genes encoding seed storage proteins are modulated to effect a change in seed storage protein profile of transgenic plants. Modification of the seed storage protein profile can result in production of novel soy protein products with unique and valuable functional characteristics.

Gene expression in plants uses regulatory sequences that are functional in such plants. The expression of foreign genes in plants is well-established (De Blaere et al. (1987) *Meth. Enzymol.* 153:277-291). The source of the promoter chosen to drive the expression of the fragments of the invention is not critical provided it has sufficient transcriptional activity to accomplish the invention by decreasing the expression of the target seed storage protein genes. Preferred promoters include strong constitutive plant promoters, such as those directing the 19S and 35S transcripts in cauliflower mosaic virus (Odell, J. T. et al. (1985) *Nature* 313:810-812; Hull et al. (1987) *Virology* 86:482-493). Particularly preferred promoters are those that allow seed-specific expression.

Examples of seed-specific promoters include, but are not limited to, the promoters of seed storage proteins, which can represent up to 90% of total seed protein in many plants. The seed storage proteins are strictly regulated, being expressed almost exclusively in seeds in a highly tissue-specific and stage-specific manner (Higgins et al. (1984) *Ann. Rev. Plant Physiol.* 35:191-221; Goldberg et al. (1989)

Cell 56:149-160). Moreover, different seed storage proteins may be expressed at different stages of seed development.

Expression of seed-specific genes has been studied in great detail (See reviews by Goldberg et al. (1989) *Cell* 56:149-160 and Higgins et al. (1984) *Ann. Rev. Plant Physiol.* 35:191-221). There are currently numerous examples of seed-specific expression of seed storage protein genes (natural or chimeric) in transgenic dicotyledonous plants; in general, temporal and spatial expression patterns are maintained. The promoters used in such examples could potentially be used to affect the present invention. These include genes from dicotyledonous plants for bean β -phaseolin (Sengupta-Gopalan et al. (1985) *Proc. Natl. Acad. Sci. USA* 82:3320-3324; Hoffman et al. (1988) *Plant Mol. Biol.* 11:717-729), bean lectin (Voelker et al. (1987) *EMBO J.* 6:3571-3577), soybean lectin (Okamuro et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:8240-8244), soybean Kunitz trypsin inhibitor (Perez-Grau et al. (1989) *Plant Cell* 1:095-1109), soybean β -conglycinin (Beachy et al. (1985) *EMBO J.* 4:3047-3053; pea vicilin (Higgins et al. (1988) *Plant Mol. Biol.* 11:683-695), pea convicilin (Newbigin et al. (1990) *Planta* 180:461-470), pea legumin (Shirsat et al. (1989) *Mol. Gen. Genetics* 215:326-331), rapeseed napin (Radke et al. (1988) *Theor. Appl. Genet.* 75:685-694) and *Arabidopsis thaliana* 2S albumin (Vandekerckhove et al. (1989) *BioTechnology* 7:929-932).

Of particular use in the expression of the nucleic acid fragment of the invention will be the heterologous promoters from several soybean seed storage protein genes such as those for the Kunitz trypsin inhibitor (KTI; Jofuku et al. (1989) *Plant Cell* 1:1079-1093; glycinin (Nielson et al. (1989) *Plant Cell* 1:313-328), and β -conglycinin (Harada et al. (1989) *Plant Cell* 1:415-425). The skilled artisan will recognize that attention must be paid to differences in temporal regulation endowed by different seed promoters. For example, the promoter for the α -subunit gene is expressed a few days before that for the β -subunit gene (Beachy et al. (1985) *EMBO J.* 4:3047-3053), so that the use of the β -subunit gene is likely to be less useful for suppressing α -subunit expression.

Also of potential use, but less preferred, will be the promoters of genes involved in other aspects of seed metabolism, such as lipid or carbohydrate biosynthesis. In summary, the skilled artisan will have no difficulty in recognizing that any promoter of sufficient strength and appropriate temporal expression pattern can potentially be used to implement the present invention. Similarly, the introduction of enhancers or enhancer-like elements into the promoter regions of either the native or chimeric nucleic acid fragments of the invention would result in increased expression to accomplish the invention. This would include viral enhancers such as that found in the 35S promoter (Odell et al.

(1988) *Plant Mol. Biol.* 10:263-272). enhancers from the opine genes (Fromm et al. (1989) *Plant Cell* 1:977-984), or enhancers from any other source that result in increased transcription when placed into a promoter operably linked to the nucleic acid fragment of the invention.

5 Of particular importance is the DNA sequence element isolated from the gene encoding the α -subunit of β -conglycinin that can confer a 40-fold, seed-specific enhancement to a constitutive promoter (Chen et al. (1989) *Dev. Genet.* 10:112-122). One skilled in the art can readily isolate this element and insert it within the promoter region of any gene in order to obtain seed-specific enhanced
10 expression with the promoter in transgenic plants. Insertion of such an element in any seed-specific gene that is normally expressed at times different than the β -conglycinin gene will result in expression of that gene in transgenic plants for a longer period during seed development.

Any 3' non-coding region capable of providing a polyadenylation signal
15 and other regulatory sequences that may be required for the proper expression of the nucleic acid fragments of the invention can be used to accomplish the invention. This would include 3' ends of the native fatty acid desaturase(s), viral genes such as from the 35S or the 19S cauliflower mosaic virus transcripts, from the opine synthesis genes, ribulose 1,5-bisphosphate carboxylase, or chlorophyll
20 a/b binding protein. There are numerous examples in the art that teach the usefulness of different 3' non-coding regions.

Various methods of transforming cells of higher plants according to the present invention are available to those skilled in the art (see European Patent Publications EP-A-295,959 and EP-A-318,341). Such methods include those
25 based on transformation vectors utilizing the Ti and Ri plasmids of *Agrobacterium* spp. It is particularly preferred to use the binary type of these vectors. Ti-derived vectors transform a wide variety of higher plants, including monocotyledonous and dicotyledonous plants (Sukhapinda et al. (1987) *Plant Mol. Biol.* 8:209-216; Potrykus, (1985) *Mol. Gen. Genet.* 199:183). Other
30 transformation methods are available to those skilled in the art, such as direct uptake of foreign DNA constructs (see European Patent Publication EP-A-295,959), techniques of electroporation (Fromm et al. (1986) *Nature (London)* 319:791) or high-velocity ballistic bombardment with metal particles coated with the nucleic acid constructs (Klein et al. (1987) *Nature (London)*
35 327:70). Once transformed, the cells can be regenerated by those skilled in the art. Of particular relevance are the recently described methods to transform soybean, including McCabe et al. ((1988) *Bio/Technology* 6:923-926), Finer et al. ((1991) *In Vitro Cell. Dev. Biol.* 27:175-182) and Hinchey, M.A.W. ((1988) *Bio/Technology* 6:915-922).

Once transgenic plants are obtained by one of the methods described above, it is necessary to screen individual transgenics for those that most effectively display the desired phenotype. It is well known to those skilled in the art that individual transgenic plants carrying the same construct may differ in expression levels; this phenomenon is commonly referred to as "position effect". Thus, in the present invention different individual transformants may vary in the effectiveness of suppression of the target seed protein. The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323 have taught the feasibility of these techniques, but it is well known that their efficiency is unpredictable. Accordingly, the person skilled in the art will make multiple genetic constructs containing one or more different parts of the gene to be suppressed, since the art does not teach a method to predict which will be most effective for a particular gene. Furthermore, even the most effective constructs will give an effective suppression phenotype only in a fraction of the individual transgenic lines isolated. For example, World Patent Publications WO93/11245 and WO94/11516 teach that when attempting to suppress the expression of fatty acid desaturase genes in canola, actual suppression was obtained in less than 1% of the lines tested. In other species the percentage is somewhat higher, but in no case does the percentage reach 100. This should not be seen as a limitation on the present invention, but instead as practical matter that is appreciated and anticipated by the person skilled in this art. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds, and is not an inherent part of the invention. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that the majority of samples will be negative.

The mechanism of cosuppression remains unclear (for one review and speculation, see Flavell, R. (1994) *Proc. Natl. Acad. Sci. USA* 91:3490-3496), and therefore the exact requirements to induce it when desired are also unclear. Most examples found in the literature involve the use of all or a large part of the transcribed region of the gene to be cosuppressed to elicit the desired response. However, in at least one case (Brusslan et al. (1993) *Plant Cell* 5:667-677; Brusslan and Tobin (1995) *Plant Mol. Biol.* 27:809-813), that of the cab140 gene of Arabidopsis, the use of the promoter (as a 1.3 kb fragment) and just 14 bp of transcribed region fused to a completely unrelated gene was sufficient to result in cosuppression of the endogenous cab140 gene as well as the introduced chimeric gene. This result is unusual and apparently quite unpredictable, as numerous other

promoter-leader (the 5' untranslated leader being defined as the region between the start of transcription and the translation initiation codon) units have been used to drive chimeric genes successfully. Flavell speculates that some or many genes (including members of multigene families such as those encoding seed proteins) may have evolved so as to avoid the mechanisms of cosuppression, while others have not, providing a potential further level of regulation as genomes evolve. Thus, the instant observation that the promoter and leader of the conglycinin gene can be used to suppress expression of endogenous conglycins while the other portion of the transgene (beyond the initiation codon) can be used to suppress a completely unrelated gene is unique.

EXAMPLES

The present invention is further defined by the following examples. It will be understood that the examples are given for illustration only and the present invention is not limited to uses described in the examples. The present invention can be used to generate transgenic soybean plants with altered levels of various seed storage proteins. From the above discussion and the following examples, one skilled in the art can ascertain, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. All such modifications are intended to fall within the scope of the intended claims.

Detailed procedures for DNA manipulation, such as use of restriction endonuclease enzymes, other modifying enzymes, agarose gel electrophoresis, nucleic acid hybridization, and transformation of *E. coli* with plasmid DNA are described in Sambrook et al. (1989) Molecular Cloning, A Laboratory manual, 2nd ed, Cold Spring Harbor Laboratory Press (hereinafter "Maniatis"). All restriction enzymes and other modifying enzymes were obtained from Gibco BRL (Gaithersburg, MD).

EXAMPLE 1

To determine whether the expression of β -conglycinin in developing soybean cotyledons could be the target of cosuppression, truncated cDNA fragments of the α and α' subunits of β -conglycinin were prepared using a reverse transcriptase polymerase chain reaction kit (Geneamp™ RNA PCR Kit; Perkin Elmer Cetus). The upper primer, ConS, is homologous to nucleotides 5-19 of the α and α' subunit cDNA sequences obtained from the EMBL/GenBank/DBJ databases. To aid cloning, additional nucleotides were added to the 5' end to code for an Nco I restriction site. The lower primer, Con 1.4a, is complementary to nucleotides 1370-1354 of SEQ ID NO:1 and 1472-1456 of SEQ ID NO:2, representing the sequences of the α and α' cDNAs, respectively. To aid in cloning, additional nucleotides were added to the 5' end to introduce a Kpn I

restriction site. The nucleotide sequences of PCR primers ConS and Con1.4a are shown below.

5 ConS 5'-CGTACCATGGTGAGAGCGCGTTCC-3' (SEQ ID NO:4)
Nco I
Con1.4a 5'-CGGTACCGAATTGAAGTGTGGTAG-3' (SEQ ID NO:5)
Kpn I

RNA isolated from developing soybean seeds was reverse-transcribed using either the kit-supplied random hexamers, or Con1.4a, following the manufacturer's protocol. The resulting cDNA fragments were amplified in the PCR (Polymerase Chain Reaction) reaction using a mixture of ConS and Con1.4a. Reactant concentrations were as described in the manufacturer's protocols. The following program was used: a) one cycle of 2 minutes at 95°C; b) 35 cycles of: 1.5 minutes at 50°C (annealing), 5 minutes at 70°C (extension), 1.5 minutes at 95°C (denaturation); and c) one cycle of 2 minutes at 50°C followed by 10 minutes at 68°C. Fifteen microliters of each of the PCR reaction mixes was analyzed by agarose gel electrophoresis. Reactions resulted in PCR products of the expected sizes: 1.47 kb for α' and 1.37 kb for α . The truncated cDNA fragments from the remainder of the reaction mixes were purified using the Wizard™ PCR Preps DNA Purification System kit (Promega).

The purified reaction mix containing the α and α' fragments, which because of the primers used, included Nco I restriction sites at the 5' ends and Kpn I restriction sites at the 3' ends, were digested with Kpn I and Nco I restriction enzymes. The α cDNA fragment was recovered following gel electrophoresis, designated as fragment F8, and directionally cloned (sense orientation) into pCW109 (Fig. 1) and pML70 (Fig. 2) using the Nco I to Kpn I sites present in both plasmids. F8 was confirmed as α by PCR using a nested set of primers (Con.09 and Con.8) related to ConS and Con1.4a, and distinguished from α' by digestion of pCW109/F8 plasmid with Hind III, Nco I, Kpn I, and Pst I (α does not contain a Pst I site whereas α' does).

35 Con.8 5'-TCTCGGTCGTCGTTGTT-3' (SEQ ID NO:7)

The transcriptional unit KTi promoter/truncated α /Kti 3' end was released from plasmid pML70/F8 by restriction digest with BamHI, gel isolated, and labeled as F11. F11 was then cloned into pKS18HH (Fig. 3) at the BamHI site. 40 pKS18HH is a plasmid construction containing the following genetic elements:

(i) T7 promoter/Hygromycin B Phosphotransferase (HPT)/T7 Terminator

- Sequence; (ii) 35S promoter from cauliflower mosaic virus (CaMV)/Hygromycin B Phosphotransferase (HPT)/Nopaline Synthase (NOS) 3' from *Agrobacterium tumefaciens* T-DNA; and (iii) pSP72 plasmid vector (Promega) with beta-lactamase coding region removed. One skilled in the art of molecular biology can
- 5 ligate the above three components into a single plasmid vector using well known protocols (Maniatis).

- The Hygromycin B Phosphotransferase (HPT) gene was isolated by PCR amplification from *E. coli* strain W677 containing a *Klebsiella*-derived plasmid pJR225 (Gritz L., and Davies J. (1983) *Gene* 25:179-188). pKS18HH contains
- 10 the CaMV 35S/HPT/NOS cassette for constitutive expression of the HPT enzyme in plants, such as soybean. The pKS18HH plasmid also contains the T7 promoter/HPT/T7 terminator cassette for expression of the HPT enzyme in certain strains of *E. coli*, such as NovaBlue™ (DE3) (Novagen) that are lysogenic for lambda DE3 (which carries the T7 RNA Polymerase gene under lacUV5 control).
- 15 pKS18HH also contains three unique restriction endonuclease sites suitable for cloning of genes into this vector. Thus, the pKS18HH plasmid vector allows the use of Hygromycin B for selection in both *E. coli* and plants. Confirmation of insertion and orientation of the F11 fragment was accomplished by digestion with HindIII. A clone with the F11 fragment in clockwise orientation was selected and
- 20 labeled pJol (Fig. 4).

Transformation of Somatic Embryo Cultures

The following stock solutions and media were used for transformation and propagation of soybean somatic embryos:

<u>Stock Solutions</u>		<u>Media</u>	
<u>MS Sulfate 100x stock</u>		<u>SB55 (per Liter)</u>	
MgSO ₄	7H ₂ O	37.0	10 mL of each MS stock
MnSO ₄	H ₂ O	1.69	1 mL of B5 Vitamin stock
ZnSO ₄	7H ₂ O	0.86	0.8 g NH ₄ NO ₃
CuSO ₄	5H ₂ O	0.0025	3.033 g KNO ₃
			1 mL 2,4-D (10 mg/mL stock)
<u>MS Halides 100x stock</u>		<u>SB103 (per Liter)</u>	
CaCl ₂	2H ₂ O	44.0	0.667 g asparagine
KI		0.083	pH 5.7
CoCl ₂	6H ₂ O	0.00125	
KH ₂ PO ₄		17.0	
H ₃ BO ₃		0.62	1 pk. Murashige & Skoog salt mixture (Gibco BRL)
Na ₂ MoO ₄	2H ₂ O	0.025	60 g maltose

Na ₂ EDTA	3.724	2 g gelrite
FeSO ₄ 7H ₂ O	2.784	pH 5.7 (For SB103 plus charcoal, add 5 g charcoal)
<u>B5 Vitamin stock</u>		<u>SB148 (per Liter)</u>
<i>myo</i> -inositol	100.0	1 pk. Murashige & Skoog salt mixture (Gibco BRL)
nicotinic acid	1.0	60 g maltose
pyridoxine HCl	1.0	1 mL B5 vitamin stock
thiamine	10.0	7 g agarose pH 5.7

Soybean embryonic suspension cultures were maintained in 35 mL liquid media (SB55) on a rotary shaker (150 rpm) at 28°C with a mix of fluorescent and incandescent lights providing a 16/8 h day/night schedule. Cultures were subcultured every 2 to 3 weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid media.

Soybean embryonic suspension cultures were transformed with pJo1 by the method of particle gun bombardment (see Klein et al. (1987) *Nature* 327:70). A DuPont Biolistic™ PDS1000/He instrument was used for these transformations. Five µL of pJo1 plasmid DNA (1 µg/µL), 50 µL CaCl₂ (2.5 M), and 20 µL spermidine (0.1 M) were added to 50 µL of a 60 mg/mL 1 mm gold particle suspension. The particle preparation was agitated for 3 minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles were then washed once with 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension was sonicated three times for 1 second each. Five µL of the DNA-coated gold particles were then loaded on each macro carrier disk.

Approximately 300 to 400 mg of two week old suspension culture was placed in an empty 60 mm x 15 mm petri dish and the residual liquid removed from the tissue by pipette. The tissue was placed about 3.5 inches away from the retaining screen and bombarded twice. Membrane rupture pressure was set at 1000 psi and the chamber was evacuated to -28 inches of Hg. Two plates were bombarded per construct per experiment. Following bombardment, the tissue was divided in half and placed back into liquid media and cultured as described above.

Fifteen days after bombardment, the liquid media was exchanged with fresh SB55 containing 50 mg/mL hygromycin. The selective media was refreshed weekly. Six weeks after bombardment, green, transformed tissue was isolated and inoculated into flasks to generate new transformed embryonic suspension cultures.

Transformed embryonic clusters were removed from liquid culture media and placed on a solid agar media, SB103, plus 0.5% charcoal to begin maturation. After 1 week, embryos were transferred to SB103 media minus charcoal. After 3 weeks on SB103 media, maturing embryos were separated and placed onto
5 SB148 media. Conditions during embryo maturation were 26° C, with a mix of fluorescent and incandescent lights providing a 16/8 h day/night schedule. After 6 weeks on SB148 media, embryos were analyzed for the expression of the β -conglycinin subunit proteins. Each embryonic cluster gave rise to 5 to 20 somatic embryos.

10 Analysis of Transformed Somatic Embryos

Initial experiments were performed to determine when the α , α' and β subunits of β -conglycinin could be visualized during somatic embryo maturation by SDS-PAGE gel electrophoresis. Cotyledons of non-transformed embryos (generated as above, except they did not undergo bombardment) were dissected
15 from embryos at 6, 8, 10, and 12 weeks after initiating maturation and kept frozen at -80°C until analyzed. Cotyledonary tissue was weighed, 10 μ L/mg tissue of extraction buffer was added, and the tissue ground in a Pellet Pestle Disposable Mixer (Kimble/Kontes). Extraction buffer consisted of 50 mM Tris-HCl (pH 7.5), 10 mM β -mercaptoethanol (BME), and 0.1% SDS. The samples were then
20 microfuged at 12,000 rpm for 10 minutes and supernatant remove to a new microfuge tube by pipette. Extracts were kept frozen at -20° C until used.

For SDS-PAGE analysis, 8 μ L of (2x) loading buffer was added to 8 μ L of sample extract. The (2x) loading buffer consisted of 100 mM Tris-HCl (pH 7.5), 4% SDS, 0.2% bromophenol blue, 15% glycerol, and 200 mM β ME. The mixture
25 was heated at 95°C for 4 minutes. Sample mixes were then microfuged (12,000 rpm for 20 seconds) and loaded onto a 10% precast Ready Gel™ (Bio-Rad) that was assembled into a mini-Protein II Electrophoresis Cell (Bio-Rad). Bio-Rad Tris/Glycine/SDS Buffer was used as the running buffer and voltage was a constant 125V. In addition to sample extracts, each gel contained
30 one lane with a molecular weight standard (Bio-rad SDS-PAGE standard, low range) and one lane with total soybean seed protein extracted from commercial defatted soy flour. Upon completion, the gels were stained with Coomassie Brilliant Blue and destained (Maniatis) in order to visualize proteins. Gels were photographed, placed in a sealed bag with water, and stored in the refrigerator.
35 Results indicated that the α , α' and β subunits of β -conglycinin were detectable in the cotyledons of somatic embryos between 8 and 10 weeks after the start of maturation.

Analysis of transformed embryos was carried out at 10 weeks after the start of maturation using the methods described above. Two embryos per clone

were analyzed initially. Additional embryos were analyzed if suppression of the β -conglycinin subunits was observed in the two embryos. Table 1 presents the results of this analysis, wherein the presence or absence of each β -conglycinin subunit is indicated by a (+) or (-), respectively.

5

TABLE 1

Clone	Embryo	α	α'	β
Jo1-1	1	-	-	+
	2	-	-	+
	3	+	+	+
	4	-	-	+
	5	+	+	+
Jo1-2	1	+	+	+
	2	+	+	+
Jo1-3	1	+	+	+
	2	+	+	+
Jo1-4	1	-	-	-
	2	-	-	-
	3	-	-	-
	4	+	+	+
	5	-	-	-
Jo1-5b	1	+	+	+
	2	+	+	+
Jo1-5c	1	-	-	+
	2	-	-	+
Jo1-5d	1	+	+	+
	2	+	+	+
Jo1-6a	1	-	-	+
	2	-	-	+
	3	-	-	+
	4	-	-	+
	5	+	+	+
Jo1-6b	1	+	+	+
	2	+	+	+
Jo1-6c	1	+	+	+
Jo1-6d	1	+	+	+
	2	+	+	+
Jo1-6d	1	+	+	+
	2	+	+	+
Jo1-6e	1	+	+	+
	2	+	+	+
Jo1-7a	1	-	-	+
	2	+	+	+
Jo1-7b	1	-	-	+
Jo1-8a	1	+	+	+
Jo1-8b	1	+	+	+

	2	+	+	+
Jo1-9a	1	+	+	+
	2	+	+	+
Jo1-9b	1	+	+	+
	2	-	-	+
Jo1-9c	1	+	+	+
Jo1-10	1	-	-	+
	2	+	+	+

Seven transgenic clones gave rise to embryos in which the expression α and α' was suppressed. In addition, one clone (Jo1-4) gave rise to embryos in which all three β -conglycinin subunits were suppressed. This result is surprising as the truncated α transgene sequence overlaps with only a 0.75 kb portion of the total 1.32 kb β subunit cDNA. Overall, there is only 52% similarity between the truncated α transgene and the β subunit cDNA. With the knowledge at hand, the truncated α transgene would not be considered to possess sufficient similarity of structure to "cosuppress" the β subunit of the β -conglycinin gene.

An example of an SDS-PAGE analysis is shown in Figure 5. Lanes 1-3 are extracts of three cotyledons dissected from embryos generated from clone Jo1-1. Lanes 4 and 5 are protein molecular weight standards and soy protein standard derived from seed, respectively. Lanes 6-8 are extracts of cotyledons dissected from embryos generated from clone Jo1-4. The protein pattern in lane 2 is an example of embryos in which both α and α' are co-suppressed. The protein patterns in lanes 6 and 8 are examples of embryos where all the subunits comprising β -conglycinin are suppressed.

EXAMPLE 2

To determine if expression of β -conglycinin could be suppressed in developing cotyledons by cosuppression using the β -conglycinin promoter region, a plasmid, designated pBS43, containing a *Glycine max* microsomal delta-12 desaturase cDNA (GmFad 2-1) sequence (Heppard et al., (1996) *Plant Physiol.* 110:311-319; GenBank Acc. No. L43920) under control of the soybean β -conglycinin promoter (Beachy et al., (1985) *EMBO J.* 4:3047-3053), was constructed. The construction of this vector was facilitated by the use of the following plasmids: pMH40, pCST2 and pBS13. The plasmid constructions detailed below are described in part in United States Patent Application No. USSN 08/262,401 and World Patent Publication No. WO94/11516, both of which are incorporated herein by reference.

The pMH40 vector was derived from plasmid pGEM9z, a commercially available cloning vector (Promega Biotech) by the insertion a 1.4 kb 35S promoter region from CaMV (Odell et al. (1985) *Nature* 303:810-812; Harpster et al. (1988)

Mol. Gen. Genet. 212:182-190) coupled to the β -glucuronidase gene from *E. coli*. This was a 1.85 kb fragment encoding the enzyme β -glucuronidase (Jefferson et al. (1986) *PNAS USA* 83:8447-8451) and a 0.3 kb DNA fragment containing the transcription terminator from the nopaline synthase gene of the Ti-plasmid of *Agrobacterium tumefaciens* (Fraley et al. (1983) *PNAS USA* 80:4803-4807).

- The vector pCST2 was derived from vectors pML18 and pCW109A. The plasmid pCW109A contains the soybean β -conglycinin promoter sequence and the phaseolin 3' untranslated region and is a modified version of vector pCW109 which was derived from the commercially available plasmid pUC18 (Gibco-BRL). The vector pCW109 was made by inserting into the Hind III site of the cloning vector pUC18 a 555 bp 5' non-coding region (containing the promoter region) of the β -conglycinin gene followed by the multiple cloning sequence containing the restriction endonuclease sites for Nco I, Sma I, Kpn I and Xba I, then 1174 bp of the common bean phaseolin 3' untranslated region into the Hind III site. The β -conglycinin promoter region used is an allele of the published β -conglycinin gene (Doyle et al., (1986) *J. Biol. Chem.* 261:9228-9238) due to differences at 27 nucleotide positions. Further sequence description of this gene may be found World Patent Publication W091/13993.

- To facilitate use in antisense constructions, the Nco I site and potential translation start site in the plasmid pCW109 was destroyed by digestion with Nco I, mung bean exonuclease digestion and religation of the blunt site to give the modified plasmid pCW109A.

- The vector pML18 consists of the non-tissue specific and constitutive cauliflower mosaic virus (35S) promoter (Odell et al., (1985) *Nature* 313:810-812; Hull et al., (1987) *Virology* 86:482-493), driving expression of the neomycin phosphotransferase gene (Beck et al. (1982) *Gene* 19:327-336) followed by the 3' end of the nopaline synthase gene including nucleotides 848 to 1550 (Depicker et al. (1982) *J. Appl. Genet.* 1:561-574). This transcriptional unit was inserted into the commercial cloning vector pGEM9z (Gibco-BRL) and is flanked at the 5' end of the 35S promoter by the restriction sites Sal I, Xba I, Bam HI and Sma I, in that order. An additional Sal I site is present at the 3' end of the NOS 3' sequence and the Xba I, Bam HI and Sal I sites are unique. The plasmid pML18 was digested with Xba I, the single stranded ends were filled-in using the Klenow fragment of DNA polymerase I, and the product was ligated in order to remove the Xba I site. The resulting plasmid was designated pBS16.

The plasmid pCW109A was digested with Hind III and the resulting 1.84 kb fragment, which contained the β -conglycinin/antisense delta-12 desaturase cDNA/phaseolin 3' untranslated region, was gel isolated. This 1.84 kb fragment was ligated into the Hind III site of pBS16. A plasmid containing the

insert in the desired orientation yielded a 3.53 kb and 4.41 kb fragment when digested with Kpn I and this plasmid was designated pCST2.

The vector pBS13 was used as the source of the GmFad2-1 cDNA, which encodes the soybean microsomal delta12-desaturase and possesses the sequence as disclosed in GenBank Acc. No. L43920. The vector pBS13 was derived from the vector pML70 (Fig. 1), which contains the KTi3 promoter and the KTi3 3' untranslated region and was derived from the commercially available vector pTZ18R (Pharmacia) via the intermediate plasmids pML51, pML55, pML64 and pML65. A 2.4 kb Bst BI/Eco RI fragment of the complete soybean KTi3 gene (Jofuku and Goldberg (1989) *Plant Cell* 1:1079-1093), which contains all 2039 nucleotides of the 5' untranslated region and 390 bases of the coding sequence of the KTi3 gene ending at the Eco RI site corresponding to bases 755 to 761 of the sequence described in Jofuku (*supra*), was ligated into the Acc I/Eco RI sites of pTZ18R to create the plasmid pML51. To destroy an Nco I site in the middle of the 5' untranslated region of the KTi3 insert, plasmid pML51 was cut with Nco I, the singled stranded ends were filled-in using the Klenow fragment of DNA polymerase I, and the product was religated resulting in the plasmid pML55. The plasmid pML55 was partially digested with Xmn I/Eco RI to release a 0.42 kb fragment, corresponding to bases 732 to 755 of the above cited sequence, which was discarded. A synthetic Xmn I/Eco RI linker containing an Nco I site, was constructed by making a dimer of complementary synthetic oligonucleotides consisting of the coding sequence for an Xmn I site (5'-TCTTCC-3') and an Nco I site (5'-CCATGGG-3') followed directly by part of an Eco RI site (5'-GAAGG-3'). The Xmn I and Nco I/Eco RI sites were linked by a short intervening sequence (5'-ATAGCCCCCAA-3'). This synthetic linker was ligated into the Xmn I/Eco RI sites of the 4.94 kb fragment to create the plasmid pML64. The 3' untranslated region of the KTi3 gene was amplified from the sequence described in Jofuku (*supra*) by standard PCR protocols (Perkin Elmer Cetus, GeneAmp PCR kit) using the primers ML51 and ML52. Primer ML51 contained the 20 nucleotides corresponding to bases 1072 to 1091 of the above cited sequence with the addition of nucleotides corresponding to Eco RV (5'-GATATC-3'), Nco I (5'-CCATGG-3'), Xba I (5'-TCTAGA-3'), Sma I (5'-CCCGGG-3') and Kpn I (5'-GGTACC-3') sites at the 5' end of the primer. Primer ML52 contained to the exact complement of the nucleotides corresponding to bases 1242 to 1259 of the above cited sequence with the addition of nucleotides corresponding to Sma I (5'-CCCGGG-3'), Eco RI (5'-GAATTC-3'), Bam HI (5'-GGATCC-3') and Sal I (5'-GTCGAC-3') sites at the 5' end of the primer. The PCR-amplified 3' end of the KTi3 gene was ligated into the Nco I/Eco RI sites of pML64 to create the plasmid pML65. A synthetic multiple cloning site linker was constructed by

making a dimer of complementary synthetic oligonucleotides consisting of the coding sequence for Pst I (5'-CTGCA-3'), Sal I (5'-GTCGAC-3'). Bam HI (5'-GGATCC-3') and Pst I (5'-CTGCA-3') sites. The linker was ligated into the Pst I site (directly 5' to the KTi3 promoter region) of pML65 to create the plasmid pML70.

The 1.46 kb Sma I/Kpn I fragment from soybean delta-12 desaturase cDNA, GmFad2-1 (GenBank Acc. No. L43920), was ligated into the corresponding sites in pML70 resulting in the plasmid pBS10. The desaturase cDNA fragment was in the reverse (antisense) orientation with respect to the KTi3 promoter in pBS10. The plasmid pBS10 was digested with Bam HI and a 3.47 kb fragment, representing the KTi3 promoter/antisense desaturase cDNA/KTi3 3' end transcriptional unit was isolated by agarose gel electrophoresis. The vector pML18 consists of the non-tissue specific and constitutive cauliflower mosaic virus (35S) promoter (Odell et al., (1985) *Nature* 313:810-812; Hull et al., (1987) *Virology* 86:482-493), driving expression of the neomycin phosphotransferase gene (Beck et al. (1982) *Gene* 19:327-336) followed by the 3' end of the nopaline synthase gene including nucleotides 848 to 1550 (Depicker et al. (1982) *J. Appl. Genet.* 1:561-574). This transcriptional unit was inserted into the commercial cloning vector pGEM9z (Gibco-BRL) and is flanked at the 5' end of the 35S promoter by the restriction sites Sal I, Xba I, Bam HI and Sma I in that order. An additional Sal I site is present at the 3' end of the NOS 3' sequence and the Xba I, Bam HI and Sal I sites are unique. The 3.47 kb transcriptional unit released from pBS10 was ligated into the Bam HI site of the vector pML18. When the resulting plasmids were digested with Sma I and Kpn I, plasmids containing inserts in the desired orientation yielded 3 fragments of 5.74, 2.69 and 1.46 kb. A plasmid with the transcriptional unit in the correct orientation was selected and was designated pBS13.

The 1.46 kb XbaI/EcoRV fragment from pBS13 (described above) was directionally cloned into the SmaI/XbaI site of vector pCST2 (described above) to yield a plasmid designated pBS39. The 3.3 kb HindIII fragment of plasmid pBS39 was cloned into the HindIII site of plasmid pMH40 (described above) to give the plant expression vector pBS43 (Fig. 6).

Transformation of soybeans with vector pBS43 and
identification of a transgenic "Transwitch" line

The vector pBS43 was transformed into soybean meristems using the method of particle bombardment of soybean meristems (Christou et al (1990) *Trends Biotechnol.* 8:145-151). Seeds of transformed plants (i.e., from plants which had been identified as positive for GUS activity) were screened for fatty acid composition. Fatty acid methyl esters were prepared from hexane extracts of

small (approx. 10 mg) seed chips (Browse et al (1986) *Anal. Biochem.*

152:141-145). Seed chips from ten different transgenic lines were analysed and some of the R1 seeds from one of these lines, designated 260-05, had a total oleic acid content of 80-85% compared with about 20% in control seeds. This

5 phenotype is caused by the cosuppression of the endogenous Fad 2-1 gene and is the result of the insertion of two copies of pBS43 into a locus of the soybean genome designated the "Transwitch locus" (Kinney, A. J. (1995) in "Induced Mutations and Molecular Techniques for Crop Improvement", International Atomic Energy Agency, Vienna). High oleic acid R1 seeds from line 260-05, 10 which contained the Transwitch locus, were selfed and R2 seeds which were homozygous for the Transwitch locus were selected. Two of these R2 homozygous seeds (G94-1, G94-19) and seeds derived from further generations of G94-1 and G94-19 (R3, R4, R5), were selected for further analysis.

R5 seeds of G94-1 and G94-19 plants grown in both Iowa and Puerto Rico 15 were ground into a powder and approximately 1 g extracted with 5 mL of hexane. After centrifugation, the hexane was poured off and the flakes allowed to air dry. Approximately 10 mg of defatted powder was extracted as described above and analyzed by SDS-PAGE. In both transgenic lines derived from both locations, the expression of the α' and α subunits of β -conglycinin were suppressed relative to 20 control soybean lines and a standard soy flour (Fig. 7).

EXAMPLE 3

To test if β -conglycinin expression could be suppressed using antisense technology, full length cDNAs of α and α' were made using reverse transcriptase polymerase chain reaction as described above. The upper primer, ConSa, is 25 homologous to region 4-19 of both α and α' cDNA sequences with additional nucleotides added to the 5' end to code for a Kpn I restriction site. The lower primer used, Con1.9a, is homologous to regions 1818-1801 of SEQ ID NO:1, representing the α isoform, and 1920-1903 of SEQ ID NO:2, representing the α' isoform, respectively. To aid in subsequent cloning steps, additional nucleotides 30 were added to the 5' end to code for an Nco I restriction site.

ConSa 5'-ACGGTACCGATGAGAGCGCGGTTCC-3' (SEQ ID NO:8)

Kpn I

Con1.9a 5'-AACCCATGGTCAGTAAAAAGCCCTCAA-3' (SEQ ID NO:9)

Nco I

Reverse transcription and subsequent PCR reaction were carried out as described above. RNA isolated from developing soybean seeds was reverse-transcribed using either random hexamers or Con1.9a (method as detailed above).

40 The cDNA was amplified in a PCR reaction using ConSa and Con1.9a using the

- protocol detailed above. Fifteen microliters of the PCR reaction mixes were analyzed by agarose gel electrophoresis. A 1.8 kb band, the expected molecular weight for α , was observed. The remaining reaction mixes were purified using Wizard™ PCR Preps DNA Purification System kit (Promega). The α cDNA, which because of the primers used included a Kpn I site on the 5' end and an Nco I site on the 3' end, was digested with Nco I and Kpn I restriction enzymes. The resulting α cDNA was gel isolated, labeled as F10, and directionally cloned (antisense orientation) into pCW109 using the Nco I and Kpn I sites present in the plasmid. F10 was confirmed as α by PCR using nested primers (upper: Con.09 (SEQ ID NO:6); lower: Con1.4a (SEQ ID NO:5) and Con1.0 (SEQ ID NO:10)).
- Con1.0 5'-CGGGTATGGCGAGTGTT-3' (SEQ ID NO:10)

- The transcriptional unit β -conglycinin promoter/ α cDNA antisense/phaseolin 3' end was released from pCW109/F10 by partial digest with Hind III. Conditions of the partial digest were such that 6 fragments were produced (5.1 kb, 3.8 kb, 3.6 kb, 2.6 kb, 2.4 kb, and 1.2 kb). The 3.6 kb fragment containing the the transcriptional unit was gel isolated and labeled F14. F14 was then cloned into the Hind III site of pKS18HH. After confirming insertion by digestion of plasmid DNA preparations made from transformed cells with Hind III, the plasmid DNA from positive cultures was digested with Kpn I to ensure that they contained the 3.6 kb F14 fragment and not the 3.8 kb fragment from the partial digest of pCW109/F10 with Hind III. F14 contains a Kpn I site, while the 3.8 kb fragment does not. Upon confirmation, pKS18HH/F14 was labeled pJo3 (Fig. 8). Soybean embryonic suspension cultures were transformed with pJo3 as detailed above. Transformation resulted in 5 transformed clones; upon maturation each clone gave rise to 4 to 8 somatic embryos.

- Protein extracts of transformed somatic embryos were analyzed by SDS-PAGE as previously detailed. Results are presented in Table 2. The transgenic clones all gave rise to at least one somatic embryo in which the expression of both α and α' was suppressed.

TABLE 2

Clone	Embryo	α	α'	β
Jo3-1	1	-	-	+
	2	+	+	+
Jo3-2	1	-	-	+
	2	-	-	+
Jo3-2b	1	-	-	+
	2	-	-	+

The upper primer used for RT-PCR reactions of Group II (G4-7) is homologous to regions 7-22 for both cDNA's of Group II. Two lower primers were used: G4-1251 which is homologous with regions 1251-1234 of Gy4 and 1153-1135 of Gy5; or G4-1670 which is homologous to regions 1668-1653 of Gy4.

There is no similar region in Gy5. To aid in future cloning all primers contained additional nucleotides that coded for a Not I restriction site at their 5' end.

G4-7 5'-GCGGCCGCATGCCCTTCACTCTCT-3' (SEQ ID NO:19)

Not I

G4-1251 5'-GCGGCCGCTGGGAGGGTGAGGCTGTT-3' (SEQ ID NO:20)

Not I

G4-1670 5'-GCGGCCGCTGAGCCTTGTTGAGAC-3' (SEQ ID NO:21)

Not I

RNA isolated from developing soybean seeds was reverse-transcribed using either random hexamers, or G4-1251 or G4-1670 as the lower primer in the reactions. cDNA fragments were amplified using a mixture of G4-7 with either G4-1251 or G4-1670. Fifteen microliters of the PCR reaction mixes were analyzed by agarose gel electrophoresis. PCR reactions resulted in products of the expected molecular weight, approximately 1.25 kb and 1.7 kb for primer sets G4-7/G4-1251 and G4-7/G4-1670, respectively. cDNA fragments from the remainder of the reaction mixes were purified using the Wizard™ PCR Preps DNA Purification System kit (Promega). Purified cDNA's were then digested with Not I and isolated from gels.

The isolated group I cDNAs are cloned into pRB20 (Fig. 9) at the Not I site (sense orientation). After partial restriction digest with Not I and isolation of the single cut pRB20/group I linear fragments, group II cDNA are added to create final transcriptional units β -conglycinin promoter/group I cDNA (sense orientation)/phaseolin 3' end and β -conglycinin promoter/group II cDNA (sense orientation)/phaseolin 3' end. The resulting plasmids are then used to transform somatic embryonic suspension cultures using the method detailed above.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) NAME: E. I. DU PONT DE NEMOURS AND COMPANY
 - (B) STREET: 1007 MARKET STREET
 - (C) CITY: WILMINGTON
 - (D) STATE: DELAWARE
 - (E) COUNTRY: UNITED STATES OF AMERICA
 - (F) ZIP: 19898
 - (G) TELEPHONE: 302-992-5481
 - (H) TELEFAX: 302-773-0164
 - (I) TELEX: 6717325
- (ii) TITLE OF INVENTION: SUPPRESSION OF SPECIFIC
CLASSES OF SOYBEAN SEED
PROTEIN GENES
- (iii) NUMBER OF SEQUENCES: 21
- (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: DISKETTE, 3.50 INCH
 - (B) COMPUTER: IBM PC COMPATIBLE
 - (C) OPERATING SYSTEM: MICROSOFT WORD FOR WINDOWS 95
 - (D) SOFTWARE: MICROSOFT WORD 7.0
- (v) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/019,940
 - (B) FILING DATE: JUNE 14, 1996
- (vii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: LYNNE M. CHRISTENBURY
 - (B) REGISTRATION NUMBER: 30,971
 - (C) REFERENCE/DOCKET NUMBER: BB-1071

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1818 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

ATGATGAGAG CACGGTTCCC ATTACTGTG CTGGGACTTG TTTCTCTGGC TTCAGTTTCT   60
GTCTCATTTG GCATTGCTTA CTGGGAAAAA GAGAACCCCA AACACAACAA GTGTCTCCAG   120
AGTTGCAATA GCGAGAGAGA CTCGTACAGG AACCAAGCAT GCCACGCTCG TTGCAACCTC   180
CTTAAGGTGG AGAAAGAAGA ATGTGAAGAA GGTGAAATTC CACGACCACG ACCACGACCA   240
CAACACCCGG AGAGGGAACC TCAGCAACCC GGTGAGAAGG AGGAAGACGA AGATGAGCAA   300
CCACGTCCAA TCCCATTCCC ACGCCACAA CCTCGTCAAG AAGAAGACGA CGAGCAGAGA   360
GAGGAACAGG AATGCGCTCG CAAGGAGGAA AAACGCGGAG AAAAGGGGAG TGAAGAGGAA   420
GATGAGGATG AGGATGAGGA ACAAGATGAA CGTCAATTCC CATTCCCACG CCCACCTCAT   480
CAGAAGGAAG AGCGAAACGA AGAGGAAGAT GAGGATGAGG AGCAGCAGCG AGAGAGCGAA   540
GAAAGTGAAG ATTCTGAGTT ACGAAGACAT AAGAATAAGA ACCCTTTTCT CTTCGGCTCT   600
AACAGGTTCC AAACCTCTCT CAAAAACCAA TATGTTGCA TTGCGCTCCT CCAGAGGTTT   660
AACCAACGCT CCCCACAAC TCAGAATCTC CGAGACTACC GCATTTTGGA GTTCAACTCC   720
AAACCCAACA CCTCTCTTCT CCCCACCATT GCTGACGCTG ATTACCTCAT CGTTATCCTT   780
AACGGGACTG CCATTCTTTC CTGTGTGAAC AACGACGACA GAGACTCCTA CAGACTTCAA   840
TCTGGTGATG CCTGAGAGT CCCCTCAGGA ACCACATACT ATGTGGTCAA CCCTGACAAC   900
AACGAAATTC TCAGATTAAT AACACTCGCC ATACCCGTTA ACAAGCCTGG TAGATTGAG   960
AGTTTCTTCC TATCTAGCAC TGAAGCTCAA CAATCCTACT TGCAAGGATT CAGCAGGAAC  1020
ATTTTAGAGG CCTCTACGA TACCAAAATC GAGGAGATAA ACAAGGTTCT GTTTAGTAGA  1080
GAGGAAGGGC AGCAGCAAGG GGAGCAGAGG CTGCAAGAGA GCGTGATTGT GGAATCTCG  1140
AAGGAACAGA TTGCGGCACT GAGCAACCGT GCCAAATCTA GTTCAAGGAA AACCATTTCT  1200
TCTGAAGATA AACCTTTTAA CTTGAGAAGC CGGACCCCA TCTACTCCAA CAAGCTTGCG  1260
AAGTTCTTTG AGATCACCCC AGAGAAAAAC CCCAGCTTC GGGACTTGGA TATCTTCCTC  1320
AGTATTGTGG ATATGAACGA GGGAGCTCTT CTTCTACCAC ACTTCAATTG AAAGGCGATA  1380

```

GTGATACTGG TAATTAATGA AGGAGATGCA AACATTGAAC TTGTTGGCCT AAAAGAACAA	1440
CAACAGGAGC AGCAACAGGA AGAGCAACCT TTGGAAGTGC GGAAATATAG AGCCGAATTG	1500
TCTGAACAAG ATATATTTGT AATCCCAGCA GGTATCCAG TTGTGGTCAA CGCTACCTCA	1560
AATCTGAATT TCTTTGCTAT TGGTATTAAT GCCGAGAACA ACCAGAGGAA CTTCCTCGCA	1620
GGTTCGCAAG ACAATGTGAT AAGCCAGATA CCTAGTCAAG TGCAGGAGCT TGCATTCCCT	1680
GGGTCTGCAC AAGCTGTTGA GAAGCTATTA AAGAACCAAA GAGAATCCTA CTTTGTGGAT	1740
GCTCAGCCTA AGAAGAAAGA GGAGGGGAAT AAGGGAAGAA AGGTCCTTT GTCTCAATT	1800
TTGAGGGCTT TTACTGA	1818

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1920 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGATGAGAG CGCGGTCCC ATTACTGTTG CTGGGAGTTG TTTTCCTAGC ATCAGTTTCT	60
GTCTCATTTG GCATTGCGTA TTGGGAAAAG CAGAACCCCA GTCACAACAA GTGCCCTCGA	120
AGTTGCAATA GCGAGAAAGA CTCCTACAGG AACCAAGCAT GCCACGCTCG TTGCAACCTC	180
CTTAAGTGG AGGAAGAAGA AGAATGCGAA GAAGGTCAAA TTCCACGACC ACGACCACAA	240
CACCCGAGA GGAACGTCA GCAACACGGT GAGAAGGAGG AAGACGAAGG TGAGCAGCCA	300
CGTCCATTCC CATTCCCACG CCCACGCCAA CCTCATCAAG AGGAAGAGCA CGAGCAGAAG	360
GAGGAACACG AATGGCATCG CRAAGGAGGAA AAACACGGAG GAAAGGGAAG TGAAGAGGAA	420
CAAGATGAAC GTGAACACCC ACGCCACAC CAACCTCATC AAAAGGAAGA GGAAGACAC	480
GAATGGCAAC ACAAGCAGGA AAAGACCAA GGAAGGAAA GTGAAGAAGA AGAAGAAGAC	540
CAAGACGAGG ATGAGGAGCA AGACAAGAG AGCCAAGAAA GTGAAGGTTT TGAGTCTCAA	600
AGAGAACCAC GAAGACATAA GAATAAGAAC CCTTTTCACT TCAACTCTAA AAGGTTCCAA	660
ACTCTCTTCA AAAACCAATA TGCCACGTT CGCGTCCTCC AGAGGTTCAA CAAACGCTCC	720
CAACAGCTTC AGAATCTCCG AGACTACCGC ATTTTGGAGT TCAACTCCAA ACCCAACACC	780
CTTCTTCTCC CCCACCATGC TGACGCTGAT TACCTCATCG TTATCCTTAA CGGACTGCC	840
ATTCTTACCT TGGTGAACAA CGACGACGA GACTCTTACA ACCTTCAATC TGGCGATGCC	900

CTAAGAGTCC CTGCAGGAAC CACATTCTAT GTGGTTAACC CTGACAACGA CGAGAATCTC 960
 AGAATGATAG CAGGAACCCAC ATTCTATGTG GTTAACCCCTG ACAACGACGA GAATCTCAGA 1020
 ATGATAACAC TCGCCATACC CGTTAACAAA CCCGGTAGAT TTGAGAGTTT CTTCCTATCT 1080
 AGCACTCAAG CTCAACAGTC CTACTTGCAA GGGTTCAGCA AGAATATTCT AGAGGCCTCA 1140
 TACGACACCA AATTCGAGGA GATAACAAG GTTCTGTTTG GTAGAGAGGA GGGGCAGCAA 1200
 CRAAGGGGAG AGAGGCTGCA AGAGAGTGTG ATTGTGGAAA TCTCAAAGAA ACAAAATTCGG 1260
 GAACTGAGCA AACATGCCAA ATCTAGTTCA AGGAAAAACCA TTCTTCTGA AGATAAACCT 1320
 TTCAACTTGG GAAGCCGCGA CCCCATCTAT TCCAACAAGC TTGGCAAGTT GTTTGAGATT 1380
 ACCCAGAGAA ACCCTCAGCT TCGGCACTTG GATGTCTTCC TCAGTGTGTG GGATATGAAC 1440
 GAGGGAGCTC TTTTCTACC ACACTTCAAT TCAAAGGCCA TAGTGGTACT AGTGATTAAAT 1500
 GAAGGAGAAG CAAACATTGA ACTTGTGGC ATTAAGAAGC AACACAGAG GCAGCAACAG 1560
 GAAGAGCAAC CTTTGGAAAG GCGGAAATAT AGAGCTGAAT TGTCTGAACA AGATATATTT 1620
 GTAATCCAGC CAGGTTATCC AGTTATGGTC AACGCTACCT CAGATCTGAA TTCTTTGCT 1680
 TTTGGTATCA ATGCCGAGAA CAACCAGAGG AACTTCCTTG CAGGTCGAA AGACAATGTG 1740
 ATAAGCCAGA TACCTAGTCA AGTGCAGGAG CTGCGTCTCC CTAGTCTGC AAAAGATATT 1800
 GAGAACCTAA TAAAGGCCA AAGTGAGTCC TACTTTGTGG ATGCTCAGCC TCAGCAGAAA 1860
 GAGGAGGGGA ACAAGGGAAG AAAGGGTCTT TTGTCTTCAA TTTTGAGGGC TTTTACTGA 1920

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1320 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGATGAGAG TGCGGTTTCC TTTGTTGGTG TTGCTGGGAA CTGTTTCTCT GGCATCAGTT 60
 TGTGTCTCAT TAAAGGTGAG AGAGGATGAG ARTAACCCCT TCTACTTTAG AAGCTCTAAC 120
 AGCTTCCAAA CTCTCTTTGA GAACCAAAC GTTCGATTC GTCTCCTCCA GAGATTCAAC 180
 AAACGCTCCC CACAACTTGA GAACCTTCGA GACTACCGGA TTGTCCAGTT TCAGTCAAAA 240
 CCCAACACAA TCCTTCTCCC CCACCATGCT GACGCCGATT TCCTCCTCTT TGTCTTACG 300
 GGGAGAGCCA TACTTACCTT GGTGAACAAC GACGACAGAG ACTCCTACAA CCTTACCCTT 360

GGCGATGCCC AGAGAATCCC AGCTGGAACC ACTTACTATT TGGTTAACCC TCACGACCAC	420
CAGAATCTCA AATAATCAA ACTTGCCATA CCCGTCAACA AACCTGGCAG ATATGATGAT	480
TTCTTCTTAT CTAGCACTCA AGCCCAACAG TCCTACTTGC AAGGCTTCAG CCATAATATT	540
CTAGAGACCT CTTCCATAG CGAATTCGAG GAGATAAACA GGGTTTGTG TGGAGAGGAA	600
GAGGAGCAGA GGCAGCAAGA GGGAGTGATC GTGGAACCTCT CAAAGGAACA AATTCGGCAA	660
CTGAGCAGAC GTGCCAAATC TAGTTCAAGG AAAACCATTT CCTCCGAAGA TGAACCATTC	720
AACCTTGAGAA GCGCAACCC CATCTATTCC AACAACTTG GAAAGTTCTT TGAGATCACC	780
CCTGAGAAAA ACCCACAGCT TCGGGACTTG GATATCTTCC TCAGTTCTGT GGATATCAAC	840
GAAGGAGCTC TTCTTCTACC ACACCTCAAT TCAAAGGCCA TAGTGATACT AGTGATTAAAT	900
GAAGGAGATG CAAACATTGA ACTTGTGGC ATTAAGAAGC AACACAGAA GCAGAAACAG	960
GAAGAGGAAC CTTTGAAGT GCAAAGGTAC AGAGCTGAAT TGTCTGAAGA CGATGTATTT	1020
GTAATTCAG CAGCTTATCC ATTTGTCGTC AACGCTACCT CAAACCTCAA TTCTCTTGCT	1080
TTTGGTATCA ATGCTGAGAA CAACCAGAGG AACTTCCTTG CAGGCGAGAA AGACAATGTG	1140
GTAAGGCAGA TAGAAGACA AGTGCAGGAG CTTGCGTTCC CTGGGTCTGC ACAAGATGTT	1200
GAGAGGCTAT TAAAGAAGCA GAGGGAATCC TACTTTGTTG ATGCTCAGCC TCAGCAGAAG	1260
GAGGAGGGGA GTAAGGGAAG AAAGGGTCTT TTTCTTCAA TCTTAGGTGC TCTCTACTGA	1320

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGTACCATTGG TGAGAGCGCG GTTCC

25

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
CGGTACCGAA TTGAAGTGTG GTAG 24
- (2) INFORMATION FOR SEQ ID NO:6:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
TCGTCCATGG AGCGCGGTTC CCATTAC 27
- (2) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
TCTCGGTCGT CGTTGTT 17
- (2) INFORMATION FOR SEQ ID NO:8:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
ACGGTACCGA TGAGAGCGCG GTTCC 25
- (2) INFORMATION FOR SEQ ID NO:9:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AACCCATGCT CAGTAAAAAG CCCTCAA

27

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGGTATGGC GAGTGTT

17

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1488 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGCCAAGC TAGTTTTTC CCTTGTGTTT CTGCTTTTCA GTGGCTGCTG CTTGCGTTTC	60
AGTTCAGAG AGCAGCCTCA GCAAAACGAG TGCCAGATCC AAAAATCAA TGCCCTCAA	120
CCGGATAACC GTATAGATGC AGAAGGAGGG CTCATTGAGA CATGGAACCC TAACAACAAG	180
CCATTCCAGT GTGCCGGTGT TGCCCTCTCT CGCTGCACCC TCAACCGCAA CGCCCTTCGT	240
AGACCTTCCT ACACCAACGG TCCCCAGGAA ATCTACATCC AACAGGTAA GGGTATTTTT	300
GGCATGATAT ACCCGGGTGT TCCTAGCACA TTTGAAGAGC CTCAACAACC TCAACAAAGA	360
GGACAAAGCA GCAGACCACA AGACCGTCAC CAGAAGATCT ATAACTTCAG AGAGGGTGAT	420
TTGATCGCAG TGCCACTATGG TGTTCATGG TGGATGTACA ACAATGAAGA CACTCTGTT	480
GTGCGCGTTT CTATTATTGA CACCAACAGC TTGGAGAACC AGCTCGACCA GATGCCTAGG	540
AGATTCTATC TTGCTGGGAA CCAAGAGCAA GAGTTTCTAA AATATCAGCA AGAGCAAGGA	600
GGTCATCAA GCCAGAAAGG AAGCATCAG CAAGAAGAAG AAAACGAAGG AGGCAGCATA	660
TTGAGTGGCT TCACCTTGGA ATTCTTGAA CATGCATTCA GCGTGGACAA GCAGATAGCG	720
AAAAACCTAC AAGGAGAGAA CGAAGGGGAA GACAAGGGAG CCATTGTGAC AGTGAAAGGA	780
GGTCTGAGCG TGATAAAACC ACCCACGGAC GAGCAGCAAC AAAGACCCCA GGAAGAGGAA	840

GAAGAAGAAG AGGATGAGAA GCCACAGTGC AAGGGTAAAG ACAAACTACTG CCAACGCCCC 900
 CGAGGAAGCC AAAGCAAAG CAGAAGAAAT GGCATTGACG AGACCATATG CACCATGAGA 960
 CTTGCCACA ACATTGGCCA GACTTCATCA CTGACATCT ACAACCTCA AGCGGTAGC 1020
 GTCACAACCG CCACCAGCCT TGACTTCCCA GCCCTCTCGT GGCTCAGACT CAGTGTGAG 1080
 TTTGGATCTC TCCGAAGAA TGCAATGTTC GTGCCACT ACAACCTGAA CGCGAACAGC 1140
 ATAATATACG CATTGAATGG ACGGGCATTG ATACAAGTGG TGAATTGCAA CGGTGAGAGA 1200
 GTGTTTGATG GAGAGCTGCA AGAGGGACGG GTGCTGATCG TGCCACAAA CTTTGTGGTG 1260
 GCTGCAAGAT CACAGAGTGA CAACTTCGAG TATGTGTCAT TCAAGACCAA TGATACACCC 1320
 ATGATCGGCA CTCTGCGAG GGCAAACTCA TTGTTGAACG CATTACCAGA GGAAGTGATT 1380
 CAGCACACTT TCAACCTAAA AAGCCAGCAG GCCAGCAGA TAAAGAACAA CAACCCTTTC 1440
 AAGTTCCTGG TTCCACCTCA GGAGTCTCAG AAGAGAGCTG TGGCTTAG 1488

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1458 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATGGCCAAGC TTGTTCTTTC CCTTGTGTTT CTTCTTTTCA GTGGCTGCTT CGCTCTGAGA 60
 GAGCAGGCAC AGCAAAATGA GTGCCAGATC CAAAAGCTGA ATGCCCTCAA ACCGGATAAC 120
 CGTATAGAGT CGGAAGGTGG GTTCATTGAG ACATGGAACC CTAACAACAA GCCATTCCAG 180
 TGTGCCGGTG TTGCCCTCTC TCGCTGCACC CTTAACCACA ATGCCCTTCG TAGACCTTCC 240
 TACACCAAGC GTCCCCAGGA AATCTACATA CAACAAGSTA ATGGTATTTT TGGCATGATA 300
 TTCCCGGGTT GTCCTAGCAC TTATCAAGAG CCGCAAGAT CTCAGCAACG AGGACGAAGC 360
 CAGAGSCCCC AAGACCGTCA CCAAAAGGTA CATCGCTTCA GAGAGGGTGA TTTGATCGCA 420
 GTGCCTACTG GTGTTGCAAT GTGGATGTAC AACCAATGAAG ACCTCTCTGT TGTGTCCGTT 480
 TCTATTATTG ACACCAACAG CTTGAGAGAC CAGCTCGACC AGATGCCTAG GAGATTCTAT 540
 CTTGCTGGGA ACCAAGAGCA AGAGTTTCTA AATATCAGC AGCAGCAGCA AGGAGGTTC 600
 CAAAGCCAGA AAGGAAAGCA ACAAGAAGAA GAAACGAAG GAAGCAACAT ATTGAGTGGC 660
 TTGCCCCCTG AATTCTTGAA AGAAGCGTTC GCGTGAACA TGCAGATAGT GAGAAACCTA 720

CAAGGTGAGA ACGAAGAGGA GGATAGTGGA GCCATTGTGA CAGTGAAAGG AGGTCTAAGA	780
GTCCACAGCTC CAGCCATGAG GAAGCCACAG CAAGAAGAAG ATGATGATGA TGAGGAAGAG	840
CAGCCACAGT GCGTGGAGAC AGACAAAGGT TGCCAACGCC AAAGCAAAAG GAGCAGAAAT	900
GGCATTGATG AGACCATTTG CACAATGAGA CTTCGCCAAA ACATTGGTCA GAATTTCATCA	960
CCTGACATCT ACAACCTCA AGCTGGTAGC ATCACAACCG CCACCAGCTT GACTTCCCA	1020
GCCCTCTGGC TTCTCAAACCT CAGTGCCAG TATGGATCAC TCCGCAAGAA TGCTATGTTT	1080
GTGCCACACT ACACCTGAA CGCGAACAGC ATAATATACG CATTGAATGG CGCGGCATTG	1140
GTACAAGTGG TGAATTGCAA TGGTGAGAGA GTGTTTGTG GAGAGCTGCA AGAGGGAGGG	1200
GTGCTGATCG TTCCACAAAA CTTTGGGGT GCTGCAAAAT CCCAGAGCGA TAACTTTGAG	1260
TATGTGTGAT TCAAGACCAA TGATAGACCC TCGATCGGAA ACCTTGCAGG GGCAAACTCA	1320
TTGTTGAACG CATTGCCAGA GGAAGTGATT CAGCACACTT TTAACCTAAA GAGCCAGCAG	1380
GCCAGGCAGG TGAAGAACAA CAACCTTTT AGCTTCCTTG TTCCACCTCA GGAGTCTCAG	1440
AGGAGAGCTG TGGCTTAG	1458

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1446 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATGGCTAAGC TTGTTCTTTC CCTTTGTTTT CTGCTTTTCA GTGCTGCTG CTTCGCTTTC	60
AGTTTCAGAG AGCAGCCACA GCAAAACGAG TGCCAGATCC AACGCCTCAA TGCCCTAAAA	120
CCGATAACC GTATAGAGTC AGAAGGTGGC TTCATTGAGA CATGGAACCC TAACAACAAG	180
CCATTCCAGT GTGCCGGTGT TGCCCTCTCT CGCTGCACCC TCAACCGCAA CGCCCTTCGC	240
AGACCTTCCT ACACCAACGC TCCCCAGGAG ATCTACATCC AACAGGTGAT TGGTATTTTT	300
GGCATGATAT TCCCGGGTTG TCCTAGCACA TTTGAAGAGC CTCACAAAA AGGACAAAGC	360
AGCAGGCCCC AAGACCGTCA CCAGAAGATC TATCACTTCA GAGAGGGTGA TTTGATTGCA	420
GTGCCAACCG GTTTTGATA CTGGATGTAC AACAAATGAAG AACTCCTGT TGTTCGGCTT	480
TCTCTTATTG ACACCAACAG CTTCAGAAC CAGCTCGACC AGATGCCTAG GAGATTCTAT	540
CTTGCTGGGA ACCAAGAGCA AGATTTCTA CAGTATCAG CACAGAAGCA GCAAGGAGGT	600

ACTCAAAGCC AGAAAGGAAA GCGTCAGCAA GAAGAAGAAA ACGAAGGAGG CAGCATATTG	660
AGTGCGCTTCG CCCCGGAATT CTTGGAACAT GCGTTCGTCG TGGACAGGCA GATAGTGAGA	720
AAGCTACAAG GTGAGAACGA AGAGGAAGAG AAGGGTGCCA TTGTGACAGT GAAAGGAGGT	780
CTCAGCGTGA TAAGCCACCC CACGGAAGAG CAGCAACAAA GACCGAGGA AGAGGAGAAG	840
CCGATTGTG ACGAGAAGA CAAACATTGC CAAAGCCAAA GCAGAAATGG CATTGACGAG	900
ACCATTGTGA CAATGAGACT TCGCCACAAC ATTGGCCAGA CTTTCATACC TGACATCTTC	960
AACCCCTCAAG CTGGTAGCAT CACAACCGCT ACCAGCCTCG ACTTCCAGC CCTCTCGTGG	1020
CTCAAACCTA GTGCCCGATT TGGATCACTC GCAGAAGATG CTATGTTCTG GCCACACTAC	1080
AACCTGAACG CAAACAGCAT AATATACGCA TTGAATGGAC GGGCATTGGT ACAAGTGGTG	1140
AATTGCAATG GTGAGAGAGT GTTTGATGGA GAGCTGCAAG AGGACACAGT GTTAATTGTG	1200
CCACAAAACCT TTGCGGTGGC TGCAAGATCA CAGAGCGACA ACTTCGAGTA TGTTCATTTC	1260
AAGACCAATG ATAGACCCTC GATCGGCAAC CTTGCAGGTG CAAACTCATT GTTGAACGCA	1320
TTGCCGGAGG AAGTGATTCA GCAAACCTTT AACCTAAGGA GGCAGCAGGC CAGGCAGGTC	1380
AAGAACAACA ACCCTTTTCAG CTTCTGTGTT CCACCTAAGG AGTCTCAGAG GAGAGTTGTG	1440
GCTTAG	1446

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1689 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATGGGGAAGC CTTTCACTCT CTCTCTTTCT TCCTTTGCT TGCTACTCTT GTCAGTGCA	60
TGCTTTGCTA TTAGCTCCAG CAAGCTCAAC GAGTGCCAAC TCAACAACCT CAACGCGTTG	120
GAACCCGACC ACCGCGTTGA GTTCGAAGGT GGTGTGATT AAACATGGAA CTCTCAACAC	180
CCTGAGCTGA AATGCGCCGG TGCTACTGTT TCCAACTCA CCTCAACCG CAATGGCCTC	240
CAGTTGCCAT CTTACTCACC TTATCCCCGG ATGATCATCA TCGCCCAAGG GAAAGGAGCA	300
CTGAGTGCA AGCCAGGATG TCCTGAGAGC TTTGAGGAGC CACAAGAACA ATCAACACGA	360
AGAGGCTCAA GGTGCGAGAA GCAGCAGCTA CAGGACAGTC ACCAGAAGAT TCGTCACTTC	420
AATGAAGGAG ACGTACTCGT GATTCTCTCT GGTGTTCTCT ACTGGACCTA TAACACTGGC	480

GATGAACCAG TTGTGCCAT CAGTCTTCTT GACACCTCTA ACTTCAATAA CCAGCTTGAT	540
CAAAACCCCTA GGGTATTTTA CTTTGCTGGG AACCAGATA TAGAGTACCC AGAGACCATG	600
CAACAACAAC AACAGCAGAA AAGTCATGGT GGACGCAAGC AGGGGCAACA CCAGCAGGAG	660
GAAGAGGAAG AAGGTGGCAG CGTGCTCAGT GGCTTCAGCA AACACTTCTT GGCACAATCC	720
TTCAACACCA ACGAGGACAT AGCTGAGAAA CTTAGTCTC CAGACGACGA AAGGAAGCAG	780
ATCGTGACAG TGAAGGAGG TCTCAGOGTT ATCAGCCCCA AGTGGCAAGA ACAACAAGAT	840
GAAGATGAAG ATGAAGACGA AGATGATGAA GATGAACAAA TTCCCTCTCA CCCTCCTCGC	900
CGACCAAGCC ATGGAAGGCG TGAACAAGAC GAGGACGAGG ACGAAGATGA AGATAAACCT	960
CGTCCTAGTC GACCAAGCCA AGGAAAGCGT GAACAAGACC AGGACCAGGA CGAGGACGAA	1020
GATGAAGATG AAGATCAACC TCGCAAGAGC CGCGAATGGA GATCGAAAAA GACACAACCC	1080
AGAAGACCTA GACAAGAAGA ACCACGTGAA AGAGGATGGC AGACAAGAAA CGGGGTTGAG	1140
GAAAAATATCT GCACCTTGAA GCTTCACGAG AACATTGCTC GCCCTTCAGC CGCTGACTTC	1200
TACAACCCTA AAGCTGGTCG CATTAGTACC CTCACACAGC TCACCCCTCC AGCCCTCCGC	1260
CAATTCACAT TCAGTGCCCA ATATGTTGTC CTCTACAAGA ATGGAATTTA CTCTCCACAT	1320
TGGAATCTGA ATGCAACACG TGTGATCTAT GTGACTCGAG GACAAGGAAA GGTTAGAGTT	1380
GTGAATGACC AAGGGAATGC AGTGITCGAC GGTGAGCTTA GGAGGGGACA ATTGCTGGTG	1440
GTACCACAGA ACTTCGTGGT GCGGAGCAA GCCGGAGAAC AAGGATTGGA ATACATAGTA	1500
TTCAAGACAC ACCACAACGC AGTCACTAGC TACTTGAAGG ATGTGTTTAG GGCAATTCCT	1560
TCAGAGGTTT TTGCCATTG TTACAACCTT CGACAGAGTC AAGTGTCTGA GCTTAAGTAT	1620
GAAGGAAATT GGGGTCCCTT GGTCAACCCT GAGTCTCAAC AAGGCTCACC CCGTGTTAAA	1680
GTGCGATAA	1689

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1551 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATGGGGAAGC CCTTCTTAC TCTCTCTCTT TCTTCCCTTT GCTTGCTACT CTGTCGAGT	60
GCATGCTTTG CTATTACCTC CAGCAAGTTC AACGAGTGCC AACTCAACAA CCTCAACGCG	120

TTGGAACCCG ACCACCGCGT TGAGTCCGAA GGTGGTCTTA TTGAACATG GAATCTCTCAA	180
CACCCCTGAGC TGCAATGCGC CGGTGTCACT GTTCCAAAC GCACCTCTCAA CCGCAACGGC	240
TCCCACTTGC CATCTTACTT ACCTTATCCC CAAATGATCA TTGTCGTTC AAGGAAGGGA	300
GCAATTGGAT TTGCATTTC GGGATGTCCC GAGACGTTT AGAAGCCACA ACAACAATCA	360
AGCAGAAGAG GCTCAAGGTC ACAGCAGCAA CTACAAGACA GTCACCAGAA GATTCTGCAC	420
TTCAATGAAG GAGACGTACT AGTGATTCTT CTTGGTGTTT CTACTGGAC CTATAACACT	480
GGCGATGAAC CAGTTGTTGC CATCAGTCCT CTTGACACCT CCAACTTCAA CAATCAGCTT	540
GATCAAAACC CCAGAGTATT TTACCTTGCT GGGAAACCCAG ATATAGAGCA TCCCGAGACC	600
ATGCAACAAC AGCAGCAGCA GAAGAGTCAT GGTGGACGCA AGCAGGGGCA ACACCGACAG	660
CAGGAGGAAG AAGGTGGCAG TGTGCTCAGT GGCTTCAGCA AACATTTCTT AGCAACAATC	720
TTCAACACCA ACGAGGACAC AGCTGAGAAA CTTGGTCTC CAGATGACGA AAGGAAGCAG	780
ATCTGACAG TGGAGGGAGG CCTCAGCGTT ATCAGCCCCA AGTGGCAAGA ACAAGAAGAC	840
GAAGACGAAG ACGAAGACGA AGAATATGGA CGGACGCCCT CTTATCTCTC ACGACGACCA	900
AGCCATGGAA AGCATGAAGA TGACGAGGAC GAGGACGAAG AAGAAGATCA ACCTCGTCCT	960
GATCACCTC CACAGCGACC AAGCAGGCC GAAACAACAG AACCACGTGG AAGAGGATGT	1020
CAGACTAGAA ATGGGGTTGA GAAAATATT TGCACCATGA AGCTTCACGA GAACATTGCT	1080
CGCCCTTAC GTGCTGACTT CTACAACCCA AAAGCTGGTC GCATTAGCAC CCTCAACAGT	1140
CTCACCTCC CAGCCCTCCG CCAATTCCGA CTCAGTCCCC AATATGTTGT CCTCTACAGG	1200
AATGGAATTT ACTCTCCAGA TTGGAACCTG AACGCGAACA GTGTGACGAT GACTCGAGGG	1260
AAAGGAAGAG TTAGAGTGGT GAACTGCCAA GGAATGCAG TGTTTCGACG TGAGCTAAGG	1320
AGGGGACAAT TGCTAGTGGT GCCGAGAAC CCCGCGGTGG CTGAGCAAGG GGGAGAACAA	1380
GGATTGGAAT ATGTAGTGT CAAGACACAC CACAACGCC TGAGCAGCTA CATTAAAGGAT	1440
GTGTTTAGGG TAATCCTTC GGAGGTTCTT TCCAATCTT ACAACCTTGG CCAGAGTCAA	1500
GTGCGTCAGC TCAAGTATCA AGGAACTCC GGCCCTTGG TCAACCCATA A	1551

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
- GCGGCCGCAT GCCAAGCTA GTTTTT 27
- (2) INFORMATION FOR SEQ ID NO:17:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
- GCGGCCGCTG GTGGCGTTG TGA 23
- (2) INFORMATION FOR SEQ ID NO:18:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
- GCGGCCGCTC TTCTGAGCT CCT 23
- (2) INFORMATION FOR SEQ ID NO:19:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
- GCGGCCGCAT GCCCTTCACT CTCT 24
- (2) INFORMATION FOR SEQ ID NO:20:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCGGCCGCTG GGAGGGTGAG GCTGTT

26

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GCGGCCGCTG AGCCTTGTG AGAC

24

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> , line <u>1</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 US	
Date of deposit 15 June 1996	Accession Number 97614
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input type="checkbox"/> This sheet was received with the international application Authorized officer	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

Applicant's or agent's file reference number	BB1071	International application no.
--	--------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 136*bis*)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> , line <u>1</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 US	
Date of deposit 15 June 1996	Accession Number 97615
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Applicant's or agent's file reference number	BB1071	International application No.
--	--------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> , line <u>1</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 US	
Date of deposit 19 June 1996	Accession Number 97619
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer


CLAIMS

1. A method for reducing the quantity of a soybean seed storage protein in soybean seeds comprising:
 - (a) constructing a chimeric gene comprising:
 - (i) a nucleic acid fragment encoding a promoter that is functional in the cells of soybean seeds;
 - (ii) a nucleic acid fragment encoding all or a portion of a soybean seed storage protein placed in sense or antisense orientation relative to the promoter of (i); and
 - (iii) a transcriptional termination region;
 - (b) creating a transgenic soybean cell by introducing into a soybean cell the chimeric gene of (a); and
 - (c) growing the transgenic soybean cells of step (b) under conditions that result in expression of the chimeric gene of step (a)
- wherein the quantity of one or more members of a class of soybean seed storage protein subunits is reduced when compared to soybeans not containing the chimeric gene of step (a).
2. The method of Claim 1 wherein the soybean seed storage protein is selected from the group consisting of glycinin and β -conglycinin.
3. The method of Claim 1 wherein the nucleic acid fragment encoding all or a portion of a soybean seed storage protein is placed in sense orientation relative to the promoter region.
4. The method of Claim 1 wherein the nucleic acid fragment encoding all or a portion of a soybean seed storage protein is placed in antisense orientation relative to the promoter region.
5. The method of Claim 4 wherein the nucleic acid fragment encodes the alpha subunit of the β -conglycinin soybean seed storage protein.
6. The method of Claim 1 wherein at least two members of a class of soybean seed storage protein subunits are reduced when compared to soybeans not containing the chimeric gene of step (a).
7. A method for simultaneously reducing the expression of two soybean genes comprising:
 - (a) constructing a chimeric gene comprising:
 - (i) a nucleic acid fragment encoding a promoter region from a soybean seed storage protein gene; and
 - (ii) a nucleic acid fragment encoding all or a portion of a soybean protein that is not the soybean seed storage protein of (i), said nucleic acid fragment placed in sense

- or antisense orientation relative to the promoter of (i),
and (iii) a transcriptional termination region;
- (b) creating a transgenic soybean seed by introducing into a soybean seed the chimeric gene of (a); and
- 5 (c) growing the transgenic soybean seeds of step (b) under conditions that result in expression of the chimeric gene of step (a)
- wherein the quantity of one or more members of a class of soybean seed storage protein subunits and the quantity of the protein encoded by the nucleic acid fragment of (a)(ii) is reduced when compared to soybeans not containing the chimeric gene of step (a).
8. The method of Claim 7 wherein the nucleic acid fragment encoding all or a portion of a soybean protein that is not the soybean seed storage protein of (a)(i) is placed in sense orientation relative to the promoter region.
- 15 9. The method of Claim 7 wherein the nucleic acid fragment encoding all or a portion of a soybean protein that is not the soybean seed storage protein of (a)(i) is placed in antisense orientation relative to the promoter region.
10. The method of Claim 7 wherein the promoter is derived from the gene encoding the alpha subunit of the β -conglycinin soybean seed storage protein.
- 20 11. The method of Claim 7 wherein the nucleic acid fragment encoding all or a portion of a soybean protein that is not the soybean seed storage protein of (a)(i) encodes a gene involved in fatty acid biosynthesis.
12. The method of Claim 7 wherein quantity of one or more members of a class of soybean seed storage protein subunits and the quantity of the protein encoded by the nucleic acid fragment of (a)(ii) are reduced when compared to soybeans not containing the chimeric gene of step (a).
- 25 13. The method of Claim 13 wherein at least two members of a class of soybean seed storage protein subunits are reduced when compared to soybean seeds not containing the chimeric gene of step (a), and wherein the fatty acid profile of soybean seeds containing the chimeric gene of step (a) is altered when compared to soybean seeds not containing the chimeric gene of step (a).
- 30 14. A transgenic soybean plant prepared by the method of Claim 1.
15. A transgenic soybean plant prepared by the method of Claim 7.
16. Transgenic seeds derived from plants of Claim 14.
- 35 17. Transgenic seeds derived from plants of Claim 15.
18. A transgenic soybean plant wherein the quantity of one or more members of a class of soybean seed storage protein subunits is reduced in the seeds of said plant when compared to seeds derived from a non-transgenic soybean plant.

19. Transgenic seeds derived from plants of Claim 18.
20. A transgenic soybean plant wherein
 - (i) the quantity of one or more members of a class of soybean seed storage protein subunits is reduced; and
 - (ii) the oleic acid content relative to the content of other fatty acids is increased in the seeds of said plant when compared to seeds derived from a non-transgenic soybean plant.
21. Transgenic seeds derived from plants of Claim 20.

Figure 1.



Figur 2.




Figure 3.




Figure 4




Figure 5. SDS-PAGE of protein extracted from transformed somatic embryos Jo1-1 and Jo1-4 (10% gel, coomassie stained)




Figure 6.





Figure 7. SDS-PAGE of protein extracted from transformed soybean seeds of G94-1 and G94-19 (10% gel, coomassie stained)



Figur. 8.





Figure 9






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, 15/29, A01H 5/00		A3	(11) International Publication Number: WO 97/47731
		(43) International Publication Date: 18 December 1997 (18.12.97)	
(21) International Application Number: PCT/US97/09743		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 June 1997 (10.06.97)		Published With international search report.	
(30) Priority Data: 60/019,940 14 June 1996 (14.06.96) US		(88) Date of publication of the international search report: 30 September 1999 (30.09.99)	
(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): KINNEY, Anthony, J. (GB/US); 609 Lore Avenue, Wilmington, DE 19809 (US). FADER, Gary, Michael [US/US]; 100 Woods Lane, Landenberg, PA 19350 (US).			
(74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).			

(54) Title: SUPPRESSION OF SPECIFIC CLASSES OF SOYBEAN SEED PROTEIN GENES

(57) Abstract

This invention concerns the construction of transgenic soybean lines wherein the expression of genes encoding seed storage proteins are modulated to effect a change in seed storage protein profile of transgenic plants. Modification of the seed storage protein profile can result in the production of novel soy protein products with unique and valuable functional characteristics.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	KE	Kenya	NL	Netherlands	VN	Viet Nam
CG	Congo	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CH	Switzerland	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire			PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PG1/US 97/09743

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Relevant to claim No.

X WO 95 27068 A (PIONEER HI BRED INT) 12
October 1995
see page 18

1, 14, 16,
18

X	EP 0 620 281 A (MITSUBISHI) 19 October
---	--

1

A | 1994
see the whole document

20

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents

- A* document defining the general state of the art which is not considered to be of particular relevance
- E* earlier document but published on or after the international filing date
- L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O* document referring to an oral disclosure, use, exhibition or other means
- P* document published prior to the international filing date but later than the priority date claimed

- 1. "later" document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 2. "document of particular relevance": the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 3. "document of particular relevance": the claimed invention cannot be considered to involve an inventive step when the document is compared with one or more other such documents, such combination being obvious to a person skilled in the art.
- 4. "document member of the same patent family"

Date of the actual completion of the international search:

Date of mailing of the international search report

5 November 1997

25/11/1997

Name and mailing address of the ISA
European Patent Office, P. B. 5818 Patentlaan 2
NL - 2220 HV Rijswijk
Tel. +31 - 70 340-2040. Tx. 31 651 epo nl.
Fax: +31 - 70 340-3016

Authorized officer

Maddox, A

INTERNATIONAL SEARCH REPORT

Application No.

PCT/US 97/09743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 111, no. 23, 1989 Columbus, Ohio, US; abstract no. 212128, OGAWA, T., ET AL.: "Genetic improvement of seed storage proteins using three variant alleles of 7S globulin subunits in soybean (Glycine max L.)" XP002045645 see abstract & IKASHUGAKU ZASSHI, vol. 39, no. 2, 1989, pages 137-147, ---	1,2,5
A	BIOLOGICAL ABSTRACTS, vol. 98, 1994 Philadelphia, PA, US; abstract no. 83825, TAKAHASHI, K., ET AL.: "An induced mutant line lacking the alpha-subunit of beta-conglycinin soybean(Glycine max(L.) Merril)" XP002045643 see abstract & BREEDING SCIENCE, vol. 44, no. 1, 1994, pages 65-66, ---	1,2,5
A	BIOLOGICAL ABSTRACTS, vol. 101, Philadelphia, PA, US; abstract no. 137658, YAGASAKI, K., ET AL.: "Inheritance of glycinin subunits and characterization of glycinin molecules lacking the subunits in soybean (Glycine max (L.) Merr.)" XP002045644 see abstract & BREEDING SCIENCE, vol. 46, no. 1, 1996, pages 11-15, ---	1,2,5
A	BEACHY R N ET AL: "ACCUMULATION AND ASSEMBLY OF SOYBEAN BETA-CONGLYCININ IN SEEDS OF TRANSFORMED PETUNIA PLANTS" EMBO JOURNAL, vol. 4, 1985, pages 3047-3053, XP002035495 see the whole document ---	5
1 3 A	EP 0 591 530 A (RICE BREEDING RESEARCH LABORATORIES) 13 April 1994 see the whole document ---	1

-/--

INTERNATIONAL SEARCH REPORT

Application No.

US 97/09743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>UTSUMI S ET AL: "SYNTHESIS, PROCESSING AND ACCUMULATION OF MODIFIED GLYCININS OF SOYBEAN IN THE SEEDS, LEAVES AND STEMS OF TRANSGENIC TOBACCO" PLANT SCIENCE, vol. 92, no. 2, 1993, pages 191-202, XP002035496 see abstract ---</p>	2
A	<p>DATABASE WPI Section Ch, Week 9030 Derwent Publications Ltd., London, GB; Class D16, AN 90-228488 XP002045646 & JP 02 156 889 A (KIRIN BREWERY KK), 15 June 1990 see abstract ---</p>	2
A	<p>PARK, Y.-D., ET AL.: "Gene silencing mediated by promoter homology occurs at the level of transcription and results in meiotically heritable alterations in methylation and gene activity" THE PLANT JOURNAL, vol. 9, no. 2, February 1996, pages 183-194, XP002045640 see the whole document ---</p>	7
A	<p>BRUSSLAN, J.A., ET AL.: "Isolation of new promoter-mediated co-suppressed lines in Arabidopsis thaliana" PLANT MOLECULAR BIOLOGY, vol. 27, 1995, pages 809-813, XP002045641 cited in the application see the whole document ---</p>	7
A	<p>HEPPARD, E.P., ET AL.: "Development and growth temperature regulation of two different microsomal omega-6 desaturase genes in soybeans" PLANT PHYSIOLOGY, vol. 110, no. 1, January 1996, pages 311-319, XP002045642 see page 317, left-hand column ---</p>	11,20
A	<p>WO 94 11516 A (DU PONT ;LIGHTNER JONATHAN EDWARD (US); OKULEY JOHN JOSEPH (US)) 26 May 1994 see page 83 - page 98 -----</p>	11,20

INTERNATIONAL SEARCH REPORT

Information on patent family members

Application No.

/US 97/09743

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9527068 A	12-10-95	AU 2273795 A EP 0754236 A	23-10-95 22-01-97
EP 620281 A	19-10-94	CA 2120065 A CN 1105704 A JP 6335334 A US 5530192 A	01-10-94 26-07-95 06-12-94 25-06-96
EP 591530 A	13-04-94	WO 9318643 A AU 1423992 A US 5516668 A	30-09-93 21-10-93 14-05-96
WO 9411516 A	26-05-94	AU 5407594 A CA 2149223 A EP 0668919 A JP 8503364 T	08-06-94 26-05-94 30-08-95 16-04-96